<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
    <front>
        <journal-meta><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="publisher-id">PLoS</journal-id><journal-id journal-id-type="pmc">plosmed</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Medicine</journal-title></journal-title-group><issn pub-type="epub">1549-1676</issn><publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, USA</publisher-loc>
            </publisher></journal-meta>
        <article-meta><article-id pub-id-type="publisher-id">10-PLME-RA-5815R3</article-id><article-id pub-id-type="doi">10.1371/journal.pmed.1000434</article-id><article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline">
                    <subject>Evidence-Based Healthcare</subject>
                    <subject>Evidence-Based Healthcare/Bedside Evidence-Based Medicine</subject>
                    <subject>Mental Health</subject>
                    <subject>Mental Health/Mood Disorders</subject>
                </subj-group>
            </article-categories><title-group><article-title>Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific Literature</article-title><alt-title alt-title-type="running-head">Aripiprazole for Bipolar
                    Maintenance</alt-title></title-group><contrib-group>
                <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
                    <name name-style="western">
                        <surname>Tsai</surname>
                        <given-names>Alexander C.</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff1">
                        <sup>1</sup>
                    </xref>
                    <xref ref-type="corresp" rid="cor1">
                        <sup>*</sup>
                    </xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
                    <name name-style="western">
                        <surname>Rosenlicht</surname>
                        <given-names>Nicholas Z.</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff2">
                        <sup>2</sup>
                    </xref>
                </contrib>
                <contrib contrib-type="author" xlink:type="simple">
                    <name name-style="western">
                        <surname>Jureidini</surname>
                        <given-names>Jon N.</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff3">
                        <sup>3</sup>
                    </xref>
                </contrib>
                <contrib contrib-type="author" xlink:type="simple">
                    <name name-style="western">
                        <surname>Parry</surname>
                        <given-names>Peter I.</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff4">
                        <sup>4</sup>
                    </xref>
                </contrib>
                <contrib contrib-type="author" xlink:type="simple">
                    <name name-style="western">
                        <surname>Spielmans</surname>
                        <given-names>Glen I.</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff5">
                        <sup>5</sup>
                    </xref>
                </contrib>
                <contrib contrib-type="author" xlink:type="simple">
                    <name name-style="western">
                        <surname>Healy</surname>
                        <given-names>David</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff6">
                        <sup>6</sup>
                    </xref>
                </contrib>
            </contrib-group><aff id="aff1">
                <label>1</label>
                <addr-line>Robert Wood Johnson Health and Society Scholars Program, Harvard
                    University, Cambridge, Massachusetts, United States of America</addr-line>
            </aff><aff id="aff2">
                <label>2</label>
                <addr-line>Department of Psychiatry, University of California at San Francisco and
                    San Francisco Veterans Affairs Medical Center, San Francisco, California, United
                    States of America</addr-line>
            </aff><aff id="aff3">
                <label>3</label>
                <addr-line>Discipline of Psychiatry, University of Adelaide, Adelaide, South
                    Australia, Australia</addr-line>
            </aff><aff id="aff4">
                <label>4</label>
                <addr-line>Child and Adolescent Mental Health Service, Division of Mental Health,
                    Flinders University, Adelaide, South Australia, Australia</addr-line>
            </aff><aff id="aff5">
                <label>5</label>
                <addr-line>Department of Psychology, Metropolitan State University, St. Paul,
                    Minnesota, United States of America</addr-line>
            </aff><aff id="aff6">
                <label>6</label>
                <addr-line>Department of Psychological Medicine, Cardiff University, Cardiff, Wales,
                    United Kingdom</addr-line>
            </aff><contrib-group>
                <contrib contrib-type="editor" xlink:type="simple">
                    <name name-style="western">
                        <surname>Hay</surname>
                        <given-names>Phillipa J.</given-names>
                    </name>
                    <role>Academic Editor</role>
                    <xref ref-type="aff" rid="edit1"/>
                </contrib>
            </contrib-group><aff id="edit1">University of Western Sydney, Australia</aff><author-notes>
                <corresp id="cor1">* E-mail: <email xlink:type="simple">nicholas.rosenlicht@ucsf.edu</email></corresp>
                <fn fn-type="con">
                    <p><ext-link ext-link-type="uri" xlink:href="http://www.icmje.org/" xlink:type="simple">ICMJE</ext-link> criteria for authorship read and met: ACT NZR JNJ PIP
                        GIS DH. Agree with the manuscript's results and conclusions: ACT NZR
                        JNJ PIP GIS DH. Designed the experiments/the study: ACT NZR. Analyzed the
                        data: ACT NZR JNJ GIS DH. Collected data'did experiments for the study:
                        ACT NZR. Wrote the first draft of the paper: ACT NZR. Contributed to the
                        writing of the paper: ACT NZR JNJ PIP GIS DH. Contributed to the concept and
                        design of the paper and first draft: PIP.</p>
                </fn>
            <fn fn-type="conflict">
                <p>ACT receives salary support through the Robert Wood Johnson Foundation Health and
                    Society Scholars Program. The Robert Wood Johnson Foundation's stated
                    mission is to improve the health and health care of all Americans. NZR is a
                    member of the National Physicians Alliance, a not-for-profit organisation whose
                    stated primary goal is to restore physicians' primary emphasis on the core
                    values of service, integrity, and advocacy. The National Physicians Alliance
                    rejects funding from commercial health care interests and encourages its members
                    to do the same. NZR, JNJ, and PIP are members of Healthy Skepticism, an
                    international not-for-profit organisation whose stated aim is to improve health
                    by reducing harm from misleading drug promotion; GIS joined Healthy Skepticism
                    after this article was accepted for publication. GIS is a current shareholder
                    (&lt;$10,000) in a mutual fund, Vanguard Healthcare, that invests heavily
                    in pharmaceutical companies. DH reports no links to pharmaceutical companies in
                    the past 5 years. ACT is a former board member of the ethics committee, and
                    former member, of the National Physicians Alliance. ACT and NZR are former
                    members of No Free Lunch, a not-for-profit organisation whose stated mission was
                    to encourage health care providers to practice medicine on the basis of
                    scientific evidence rather than on the basis of pharmaceutical promotion. JNJ
                    was engaged by the law firm of Baum, Hedlund, Aristei &amp; Goldman to provide
                    an independent analysis of the data in Glaxo SmithKline's Study 329 of
                    paroxetine in adolescents. DH has been an expert witness in ten legal cases
                    involving antidepressant medications and one case involving the patent on
                    olanzapine (Zyprexa).</p>
            </fn></author-notes><pub-date pub-type="collection">
                <month>5</month>
                <year>2011</year>
            </pub-date><pub-date pub-type="epub">
                <day>3</day>
                <month>5</month>
                <year>2011</year>
            </pub-date><volume>8</volume><issue>5</issue><elocation-id>e1000434</elocation-id><history>
                <date date-type="received">
                    <day>3</day>
                    <month>8</month>
                    <year>2010</year>
                </date>
                <date date-type="accepted">
                    <day>23</day>
                    <month>3</month>
                    <year>2011</year>
                </date>
            </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2011</copyright-year><license><license-p>This is an open-access article, free of all copyright, and may be
                freely reproduced, distributed, transmitted, modified, built upon, or otherwise used
                by anyone for any lawful purpose. The work is made available under the Creative
                Commons CC0 public domain dedication.</license-p></license></permissions><abstract abstract-type="toc">
                <p>A systematic search of the literature reveals limited evidence to support use of
                    aripiprazole, a second-generation antipsychotic medication, in maintenance
                    therapy of bipolar disorder, despite widespread use.</p>
            </abstract><abstract>
                <sec>
                    <title>Background</title>
                    <p>Aripiprazole, a second-generation antipsychotic medication, has been
                        increasingly used in the maintenance treatment of bipolar disorder and
                        received approval from the U.S. Food and Drug Administration for this
                        indication in 2005. Given its widespread use, we sought to critically review
                        the evidence supporting the use of aripiprazole in the maintenance treatment
                        of bipolar disorder and examine how that evidence has been disseminated in
                        the scientific literature.</p>
                </sec>
                <sec>
                    <title>Methods and Findings</title>
                    <p>We systematically searched multiple databases to identify double-blind,
                        randomized controlled trials of aripiprazole for the maintenance treatment
                        of bipolar disorder while excluding other types of studies, such as
                        open-label, acute, and adjunctive studies. We then used a citation search to
                        identify articles that cited these trials and rated the quality of their
                        citations. Our evidence search protocol identified only two publications,
                        both describing the results of a single trial conducted by Keck et al.,
                        which met criteria for inclusion in this review. We describe four issues
                        that limit the interpretation of that trial as supporting the use of
                        aripiprazole for bipolar maintenance: (1) insufficient duration to
                        demonstrate maintenance efficacy; (2) limited generalizability due to its
                        enriched sample; (3) possible conflation of iatrogenic adverse effects of
                        abrupt medication discontinuation with beneficial effects of treatment; and
                        (4) a low overall completion rate. Our citation search protocol yielded 80
                        publications that cited the Keck et al. trial in discussing the use of
                        aripiprazole for bipolar maintenance. Of these, only 24 (30%)
                        mentioned adverse events reported and four (5%) mentioned study
                        limitations.</p>
                </sec>
                <sec>
                    <title>Conclusions</title>
                    <p>A single trial by Keck et al. represents the entirety of the literature on
                        the use of aripiprazole for the maintenance treatment of bipolar disorder.
                        Although careful review identifies four critical limitations to the
                        trial's interpretation and overall utility, the trial has been
                        uncritically cited in the subsequent scientific literature.</p>
                </sec>
                <sec>
                    <title/>
                    <p>
                        <italic>Please see later in the article for the Editors' Summary</italic>
                    </p>
                </sec>
            </abstract><abstract abstract-type="editor">
                <title>Editors' Summary</title>
                <sec id="s4a1a">
                    <title>Background</title>
                    <p>Bipolar disorder (manic depression) is a serious, long-term mental illness
                        that affects about 1% of adults at some time during their life. It
                        usually develops in late adolescence or early adulthood and affects men and
                        women from all backgrounds. People with bipolar disorder experience wild
                        mood swings that interfere with daily life and damage relationships. During
                        “manic” episodes, which can last several months if untreated,
                        they may feel euphoric (“high”), energetic, or irritable. They
                        may be full of ambitious plans, feel creative, and spend money recklessly.
                        They can also have psychotic symptoms—they may see or hear things that
                        are not there. During depressive episodes, affected individuals may feel
                        helpless, worthless, and suicidal. Treatments for bipolar disorder include
                        drugs to stabilize mood swings (for example, lithium and anticonvulsant
                        medications), antidepressants to treat depressive episodes, and
                        antipsychotic drugs to treat manic episodes. Psychotherapy can also help and
                        patients can be taught to recognize the signs of approaching manic or
                        depressive episodes and the triggers for these episodes.</p>
                </sec>
                <sec id="s4a1b">
                    <title>Why Was This Study Done?</title>
                    <p>Treatment of bipolar disorder is divided into three phases: acute treatment
                        lasting about 2 months to achieve remission, continuance treatment lasting
                        from months 2 through 6 to prevent relapse, and long-term maintenance
                        treatment to prevent recurrence. Second-generation (atypical) antipsychotics
                        are widely used for acute treatment of manic episodes but are also used for
                        maintenance treatment. For example, the atypical antipsychotic aripiprazole,
                        which gained US approval for this indication in 2005, is now a popular
                        choice among clinicians for treating bipolar disorder. But how much evidence
                        is there to support aripiprazole's use in the maintenance treatment of
                        bipolar disorder? Here, the researchers systematically search the published
                        literature for double-blind randomized controlled trials of aripiprazole for
                        this indication, critically analyze the quality of these trials, and
                        undertake a citation search to investigate how the results of these trials
                        have been disseminated in the scientific literature. In double-blind
                        randomized controlled trials, patients are randomly assigned to receive a
                        test drug or a control (generally, placebo), and the effects of these drugs
                        compared; patients in the trial, and physicians administering treatments,
                        would not know who is receiving the test drug or control until the trial is
                        completed.</p>
                </sec>
                <sec id="s4a1c">
                    <title>What Did the Researchers Do and Find?</title>
                    <p>The researchers' search for reports of double-blind randomized
                        controlled trials of aripiprazole for the maintenance treatment of bipolar
                        disorder using predefined criteria identified only two publications, both
                        describing a single trial—the Keck trial. Critical review of this
                        trial identified four issues that limit its interpretation for supporting
                        aripiprazole as a maintenance therapy: the trial was too short to
                        demonstrate maintenance efficacy; all the trial participants had responded
                        well to aripiprazole as an acute treatment so the generalizability of the
                        trial's results was limited; the trial design meant that some of the
                        apparent beneficial treatment results could have reflected the adverse
                        effects of abrupt medication discontinuation in the control group; and the
                        trial had a low completion rate. The researchers' citation search
                        identified 80 publications that cited the Keck trial in discussions of the
                        use of aripiprazole for maintenance treatment of bipolar disorder. Only a
                        quarter of these papers presented any numerical data from the trial, only a
                        third mentioned any of the reported adverse events, and only four papers
                        mentioned the trial's limitations.</p>
                </sec>
                <sec id="s4a1d">
                    <title>What Do These Findings Mean?</title>
                    <p>This evaluation of the evidence base supporting the use of aripiprazole for
                        the maintenance treatment of bipolar disorder shows that the justification
                        for this practice relies on the results of one published trial. Moreover,
                        the methodology and reporting of this trial mean that its results cannot
                        easily be generalized to inform the treatment of most patients with bipolar
                        disorder. Worryingly, the researchers' citation search indicates that
                        the Keck trial has been cited uncritically in the ensuing scientific
                        literature. Although the unique features of bipolar disorder make it hard to
                        undertake controlled studies of treatment options, the researchers express
                        concern that “the publication and apparently uncritical acceptance of
                        this trial may be diverting patients away from more effective
                        treatments”.</p>
                </sec>
                <sec id="s4a1e">
                    <title>Additional Information</title>
                    <p>Please access these websites via the online version of this summary at
                            <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.1000434" xlink:type="simple">http://dx.doi.org/10.1371/journal.pmed.1000434</ext-link>.</p>
                    <list list-type="bullet">
                        <list-item>
                            <p>The <ext-link ext-link-type="uri" xlink:href="http://www.nimh.nih.gov/index.shtml" xlink:type="simple">US National
                                    Institute of Mental Health</ext-link> has detailed information on
                                    <ext-link ext-link-type="uri" xlink:href="http://www.nimh.nih.gov/health/topics/bipolar-disorder/index.shtml" xlink:type="simple">bipolar disorder</ext-link>, including an <ext-link ext-link-type="uri" xlink:href="http://www.nimh.nih.gov/health/publications/bipolar-disorder-easy-to-read/index.shtml" xlink:type="simple">Easy to Read booklet</ext-link> (in English and Spanish)</p>
                        </list-item>
                        <list-item>
                            <p>The UK National Health Service Choices website provides information
                                on all aspects of <ext-link ext-link-type="uri" xlink:href="http://www.nhs.uk/Conditions/Bipolar-disorder/Pages/Introduction.aspx" xlink:type="simple">bipolar disorder</ext-link></p>
                        </list-item>
                        <list-item>
                            <p>The UK charity <ext-link ext-link-type="uri" xlink:href="http://www.mind.org.uk/" xlink:type="simple">Mind</ext-link> has
                                information on <ext-link ext-link-type="uri" xlink:href="http://www.mind.org.uk/help/diagnoses_and_conditions/bipolar_disorder_manic_depression" xlink:type="simple">bipolar disorder</ext-link> and provides links to other useful
                                organizations</p>
                        </list-item>
                        <list-item>
                            <p>MedlinePlus has links to further information on <ext-link ext-link-type="uri" xlink:href="http://www.nlm.nih.gov/medlineplus/bipolardisorder.html" xlink:type="simple">bipolar disorder</ext-link> (in English and Spanish)</p>
                        </list-item>
                    </list>
                </sec>
            </abstract><funding-group><funding-statement>The authors received no specific funding for this study. ACT received salary
                    support as a Robert Wood Johnson Health and Society Scholar at Harvard
                    University. No funding bodies had any role in the study design, data collection
                    and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts>
                <page-count count="13"/>
            </counts></article-meta>
    </front>
    <body>
        <sec id="s1">
            <title>Introduction</title>
            <p>First-generation antipsychotic medications have been used for many decades in the
                short-term treatment of acute manic episodes associated with bipolar disorder <xref ref-type="bibr" rid="pmed.1000434-Tohen1">[1]</xref>.
                Second-generation antipsychotic medications have increasingly gained popularity for
                this use as well <xref ref-type="bibr" rid="pmed.1000434-Wolfsperger1">[2]</xref>. However, their promotion for the maintenance treatment of
                bipolar disorder is a more recent phenomenon <xref ref-type="bibr" rid="pmed.1000434-Healy1">[3]</xref>–<xref ref-type="bibr" rid="pmed.1000434-Healy2">[6]</xref>. In one recently published
                nationally representative survey of physicians, mood disorders accounted for the
                majority of antipsychotic medication prescriptions <xref ref-type="bibr" rid="pmed.1000434-Mark1">[7]</xref>, and a recent shift to
                prescription of antipsychotic medications was observed in a sample of San Diego
                county Medicaid beneficiaries with bipolar disorder <xref ref-type="bibr" rid="pmed.1000434-Depp1">[8]</xref>.</p>
            <p>Traditionally, the clinical care of patients diagnosed with bipolar disorder has been
                divided into three phases (borrowed from clinical consensus about the phases of
                treatment for major depressive disorder <xref ref-type="bibr" rid="pmed.1000434-Frank1">[9]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Storosum1">[10]</xref>): treatment of acute episodes
                to symptomatic remission, continuation treatment to prevent relapse, and maintenance
                treatment to prevent recurrence. The 2 mo following recovery from the acute episode
                is commonly described as acute phase recovery, and the continuation phase of
                treatment (during which the natural course of the episode is considered still active
                even though the patient may be asymptomatic) is defined as lasting from months 2
                through 6 <xref ref-type="bibr" rid="pmed.1000434-Ghaemi1">[11]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Goodwin1">[12]</xref>. The medication used for treatment in the acute phase is
                often extended for treatment in the continuation and maintenance phases <xref ref-type="bibr" rid="pmed.1000434-Sachs1">[13]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Sachs2">[14]</xref> and in this
                context may include lithium, valproate, lamotrigine, or a second-generation
                antipsychotic medication such as olanzapine, aripiprazole, quetiapine, risperidone,
                or ziprasidone <xref ref-type="bibr" rid="pmed.1000434-Suppes1">[15]</xref>. However, although the use of second-generation
                antipsychotic medications to treat acute mania is supported by a relatively
                well-established evidence base <xref ref-type="bibr" rid="pmed.1000434-Perlis1">[16]</xref>–<xref ref-type="bibr" rid="pmed.1000434-Vieta1">[18]</xref>, efficacy in treatment of acute mania does not
                necessarily imply efficacy for maintenance or prophylaxis <xref ref-type="bibr" rid="pmed.1000434-Sachs1">[13]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Bauer1">[19]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Ghaemi2">[20]</xref>. As Goodwin and Jamison note:
                “Simply because a drug has anti-manic properties (and if continued, will
                protect against relapse back into mania in the months after the acute episode), one
                cannot assume that it will be effective in the prevention of new episodes. While
                this assumption may be true (to some extent) for lithium, it is not well supported
                by the data with respect to all the other antimanic agents” (p. 800) <xref ref-type="bibr" rid="pmed.1000434-Goodwin2">[21]</xref>.</p>
            <p>Despite the need for robust evidence on the maintenance and/or long-term prophylactic
                treatment of bipolar disorder, to date very little has been supplied in this regard
                    <xref ref-type="bibr" rid="pmed.1000434-Malhi1">[4]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Suppes1">[15]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Suppes2">[22]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Geddes1">[23]</xref>. There remains
                little consensus about recommended courses of maintenance or prophylactic treatment,
                and consequently overall psychopharmacological treatment patterns vary widely <xref ref-type="bibr" rid="pmed.1000434-Ghaemi3">[24]</xref>–<xref ref-type="bibr" rid="pmed.1000434-Zarate1">[28]</xref>. Aripiprazole,
                first approved by the U.S. Food and Drug Administration (FDA) for the treatment of
                schizophrenia in 2002, is the newest of the second-generation antipsychotic
                medications to have obtained FDA approval for use in bipolar disorder. In 2004 it
                was approved for the treatment of acute manic and mixed episodes associated with
                bipolar disorder, and in 2005 it was granted an additional indication for the
                maintenance treatment of bipolar disorder <xref ref-type="bibr" rid="pmed.1000434-US1">[29]</xref>. Since its approval, aripiprazole
                has rapidly become a popular choice among clinicians in the maintenance treatment of
                bipolar disorder. Total U.S. sales for aripiprazole (across all indications)
                increased from US$1.5 billion in 2005 to US$4 billion in 2009 <xref ref-type="bibr" rid="pmed.1000434-IMS1">[30]</xref>. In a recent study
                in which U.S.-based physicians were queried about their preferred pharmacological
                treatments for schizophrenia and bipolar disorder, only 3% of psychiatrists
                and 7% of primary care physicians named aripiprazole as their first choice
                for treating schizophrenia, whereas 23% of psychiatrists and 16% of
                primary care physicians named aripiprazole as their first choice for treating
                bipolar disorder <xref ref-type="bibr" rid="pmed.1000434-Chow1">[31]</xref>. Consistent with this survey, from 2002–2007, the
                most common indication for the prescription of aripiprazole in office-based practice
                settings was for bipolar disorder (International Classification of Diseases, Ninth
                Revision, Clinical Modification [ICD-9-CM] Diagnosis Code 296.0) <xref ref-type="bibr" rid="pmed.1000434-Diak1">[32]</xref>.</p>
            <p>In the setting of chronic illnesses such as bipolar disorder, critical appraisal of
                long-term treatments has important implications for policy making. Overall
                medication costs for the chronically ill are driven largely by decisions about the
                ongoing use of prescription medications, rather than by decisions about whether to
                initiate their use <xref ref-type="bibr" rid="pmed.1000434-Cuttler1">[33]</xref>. Spending on prescription medications is the
                fastest-growing category of the U.S. health care budget <xref ref-type="bibr" rid="pmed.1000434-Levit1">[34]</xref>, further underscoring the need
                for a rigorous evidence-based approach regarding their prescription and use. Given
                the rapid adoption and widespread use of aripiprazole in the maintenance treatment
                of bipolar disorder, we decided to review the scientific data supporting its use in
                this setting. A secondary aim of this study was to examine the diffusion of this
                data into the subsequent scientific literature.</p>
        </sec>
        <sec id="s2" sec-type="methods">
            <title>Methods</title>
            <sec id="s2a">
                <title>Primary Evidence Search</title>
                <p>We sought to identify double-blind (i.e., where participants and physicians
                    administering medications were blind to treatment assignment), randomized
                    controlled studies of aripiprazole for the maintenance treatment of bipolar
                    disorder, while also avoiding inadvertent inclusion of acute treatment studies
                    or other study designs. Therefore we required studies to have a duration greater
                    than 4 mo in order to be included in our review, and excluded open-label, acute,
                    and adjunctive studies. We searched for published literature as well as
                    unpublished and ongoing clinical trials, with no language restrictions. The
                    following systematic search strategy was employed to search PubMed:
                    “bipolar disorder”[MeSH Terms] OR
                    (“bipolar”[All Fields] AND “disorder”[All
                    Fields]) OR (“bipolar disorder”[All Fields]) AND
                    (“aripiprazole”[Substance Name] OR
                    “aripiprazole”[All Fields]) AND
                    (“maintenance”[MeSH Terms] OR
                    “maintenance”[All Fields]). We also searched Scopus
                    (including Embase and MEDLINE) using the same search terms (“bipolar
                    disorder” OR “bipolar” AND “disorder” AND
                    “aripiprazole” AND “maintenance”). We also searched
                    ClincalTrials.gov, the Cochrane Central Register of Controlled Trials (Issue 3
                    of 4, July 2010), and the World Health Organization International Clinical
                    Trials Registry Platform Search Portal using the terms
                    “aripiprazole” and “bipolar.” We did not attempt to
                    contact the manufacturer directly to inquire about possibly unpublished trials,
                    but we screened all listings on the Bristol-Myers Squibb Clinical Trials
                    Disclosure Web site under Clinical Trial Results, Psychiatric Disorders <xref ref-type="bibr" rid="pmed.1000434-BristolMyers1">[35]</xref>. All
                    searches were conducted in July 2010. And finally, we submitted a request under
                    the U.S. Freedom of Information Act <xref ref-type="bibr" rid="pmed.1000434-Gidiere1">[36]</xref> for the supplemental New
                    Drug Application (NDA) filed by the study sponsor to obtain additional labeling
                    for the use of aripiprazole as maintenance therapy in bipolar I disorder <xref ref-type="bibr" rid="pmed.1000434-US1">[29]</xref>, and we
                    searched it manually for further reference to other published or unpublished
                    studies.</p>
            </sec>
            <sec id="s2b">
                <title>Citation Search</title>
                <p>We also sought to better understand the influence of the primary evidence on the
                    broader scientific literature. To do this, we used the Web of Science(R) Science
                    Citation Index Expanded to search for articles that cited the primary evidence
                    identified through the evidence search protocol detailed above. Next, we
                    evaluated the articles on how they cited the primary evidence, using criteria
                    similar to those used in a previous study on the quality of news media reports
                    of medication trials <xref ref-type="bibr" rid="pmed.1000434-Moynihan1">[37]</xref>. Each of the citing articles was rated on three
                    quality criteria by a single study author (NZR). A 15% random sample of
                    articles (<italic>n = </italic>15) was double-coded
                    independently by another study author (ACT), and the Cohen's kappa
                    coefficient was calculated in order to assess the degree of inter-rater
                    agreement <xref ref-type="bibr" rid="pmed.1000434-Fleiss1">[38]</xref>. We chose dichotomous quality ratings to provide
                    conservative estimates of citation quality and in order to limit subjective
                    judgments by the rater. First, articles were screened for any mention of the use
                    of aripiprazole specifically for ongoing, maintenance, or prophylactic treatment
                    of bipolar disorder. If the answer to this question was “yes,” then
                    the article was further rated on the three quality criteria: (1) whether the
                    article reported any quantitative data from the primary evidence (e.g., odds
                    ratios, percentages, or <italic>p</italic>-values); (2) whether the article
                    mentioned any adverse events described in the primary evidence; and (3) whether
                    the article mentioned any limitations of the primary evidence.</p>
                <p>Although our citation search protocol was not specifically targeted towards
                    identifying treatment guidelines and review articles on pharmacological
                    treatment strategies in bipolar disorder, we manually highlighted for further
                    discussion those that were identified in the citation search. Our citation
                    search protocol likely underestimates the influence of the primary evidence
                    because we did not also use a database such as Google Scholar that could have
                    also identified guidelines implemented by hospitals, government, or other
                    institutions whose documents in this area have not been published in
                    peer-reviewed journals or indexed in services such as PubMed. However, we chose
                    to highlight treatment guidelines and reviews because they can be particularly
                    influential in shaping prescribing behavior.</p>
            </sec>
        </sec>
        <sec id="s3">
            <title>Results</title>
            <p>Our primary evidence search protocol identified 177 unique citations (<xref ref-type="fig" rid="pmed-1000434-g001">Figure 1</xref>). Of these 177 citations,
                only two publications met criteria for inclusion in our review <xref ref-type="bibr" rid="pmed.1000434-Keck1">[39]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Keck2">[40]</xref>. Searching the clinical trials
                registries yielded two listings meeting inclusion criteria, but these referred to
                the two publications already identified (<xref ref-type="fig" rid="pmed-1000434-g002">Figure 2</xref>) <xref ref-type="bibr" rid="pmed.1000434-Keck1">[39]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Keck2">[40]</xref>. Further details on the excluded
                acute and adjunctive studies are provided in <xref ref-type="supplementary-material" rid="pmed.1000434.s001">Tables S1</xref> and <xref ref-type="supplementary-material" rid="pmed.1000434.s002">S2</xref>. Two
                unpublished trials initially appeared to meet criteria for inclusion but were
                ultimately excluded. The first, Otsuka NCT00606177 <xref ref-type="bibr" rid="pmed.1000434-Otsuka1">[41]</xref>, was a 3-wk placebo-controlled
                trial of aripiprazole for treatment of acute mania with a 22-wk extension phase, but
                it was described as currently still recruiting study participants. The second, BMS
                CN138-135LT <xref ref-type="bibr" rid="pmed.1000434-BristolMyers2">[42]</xref>, was a completed 40-wk extension of a 12-wk randomized
                lithium- and placebo-controlled trial of aripiprazole for acute mania. Although the
                12-wk acute outcomes data from BMS CN138-135 were published in a peer-reviewed
                journal <xref ref-type="bibr" rid="pmed.1000434-Keck3">[43]</xref>, the
                outcomes data from the 40-wk extension have not, to our knowledge, been published
                (and the little data made available in the synopsis posted online by the
                manufacturer were inadequate for detailed critical assessment). The
                manufacturer's synopsis indicates that 4.5% of participants on
                aripiprazole completed the extension phase, compared to 8.1% for those on
                lithium. A third arm of the study, completed by 8.5% of participants,
                entailed treatment with placebo for 3 wk followed by crossover to aripiprazole.
                Finally, the supplemental NDA contained no references to additional studies,
                published or unpublished, meeting inclusion criteria (<xref ref-type="supplementary-material" rid="pmed.1000434.s003">Text S1</xref>) <xref ref-type="bibr" rid="pmed.1000434-US1">[29]</xref>.</p>
            <fig id="pmed-1000434-g001" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pmed.1000434.g001</object-id>
                <label>Figure 1</label>
                <caption>
                    <title>Publications identified for review.</title>
                    <p>These publications were identified using a systematic search of PubMed and
                        Scopus, as well as a manual search of the supplemental new drug application
                        submitted to the FDA to obtain an additional indication for the use of
                        aripiprazole in the maintenance treatment of bipolar disorder.</p>
                </caption>
                <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1000434.g001" xlink:type="simple"/>
            </fig>
            <fig id="pmed-1000434-g002" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pmed.1000434.g002</object-id>
                <label>Figure 2</label>
                <caption>
                    <title>Clinical trials identified for review.</title>
                    <p>These clinical trials were identified using a systematic search of
                        ClinicalTrials.gov, the Cochrane Central Register of Controlled Trials, the
                        World Health Organization (WHO) International Clinical Trials Registry, and
                        the Bristol-Myers Squibb Clinical Trials Disclosure Web site, as well as a
                        manual search of the supplemental new drug application submitted to the FDA
                        to obtain an additional indication for the use of aripiprazole in the
                        maintenance treatment of bipolar disorder. The “duplicates” were
                        each matched to published studies (see <xref ref-type="fig" rid="pmed-1000434-g001">Figure 1</xref>).</p>
                </caption>
                <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1000434.g002" xlink:type="simple"/>
            </fig>
            <p>The two peer-reviewed publications included in our review report the results of a
                single randomized trial (hereafter referred to as “the Keck trial”)
                implemented under the auspices of the Aripiprazole Study Group and sponsored by the
                manufacturer of the drug, Bristol-Myers Squibb Co. One publication describes the
                initial 26-wk double-blind phase <xref ref-type="bibr" rid="pmed.1000434-Keck1">[39]</xref>, and the other its 74-wk extension <xref ref-type="bibr" rid="pmed.1000434-Keck2">[40]</xref>. We also identified a post hoc
                subgroup analysis of data from the Keck trial focused on participants diagnosed with
                the rapid-cycling variant of bipolar disorder <xref ref-type="bibr" rid="pmed.1000434-Muzina1">[44]</xref>. We also identified a separate
                trial <xref ref-type="bibr" rid="pmed.1000434-Keck4">[45]</xref>, also
                authored by Keck and colleagues, examining the efficacy of aripiprazole in the
                treatment of acute manic episodes, with outcomes assessed at 3 wk. Given the paucity
                of available evidence on aripiprazole for the maintenance treatment of bipolar
                disorder, we decided to review the Keck trial <xref ref-type="bibr" rid="pmed.1000434-Keck1">[39]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Keck2">[40]</xref> in detail.</p>
            <sec id="s3a">
                <title>The Keck Trial</title>
                <p>A total of 633 adult participants meeting DSM-IV criteria for bipolar I disorder
                    were enrolled in the Keck trial. A flow chart of the trial is shown in <xref ref-type="fig" rid="pmed-1000434-g003">Figure 3</xref>. For inclusion,
                    participants must either have completed a prior 3-wk acute mania trial <xref ref-type="bibr" rid="pmed.1000434-Keck4">[45]</xref>, met
                    eligibility criteria for a prior acute mania trial but declined participation in
                    that trial, or experienced a manic or mixed episode within the prior 3 mo. The
                    publication describing the 26-wk double-blind phase <xref ref-type="bibr" rid="pmed.1000434-Keck1">[39]</xref> indicates that participants
                    were recruited from 76 sites in the U.S., Mexico, and Argentina (but does not
                    specify the numbers of sites within each country or the numbers of patients from
                    each site). Of the original enrollees, 567 entered the “stabilization
                    phase,” which consisted of open-label treatment with aripiprazole for
                    6–18 wk. Participants remained in this phase until their Young Mania
                    Rating Scale (YMRS) was ≤10 and their Montgomery-Asberg Depression Rating
                    Scale (MADRS) was ≤13 during four consecutive visits over a minimum of 6 wk.
                    206 participants completed the stabilization phase. Of these, 161 entered the
                    double-blind phase. The supplemental NDA indicates that participants who
                    completed the stabilization phase and entered randomization were derived from 45
                    sites in the U.S. (<italic>n = </italic>124), three sites
                    in Argentina (<italic>n = </italic>7), and two sites in
                    Mexico (<italic>n = </italic>30). These 161 participants
                    were assigned either to an intervention arm in which they continued taking
                    aripiprazole at the stabilizing dose
                    (<italic>n = </italic>77 or 78; both numbers are reported
                        <xref ref-type="bibr" rid="pmed.1000434-Keck2">[40]</xref>) or to
                    a placebo arm in which aripiprazole was abruptly discontinued and replaced with
                    placebo (<italic>n = </italic>83). 39 (50% of the 77
                    or 78 who entered randomization) in the intervention arm and 28 participants
                    (34%) in the placebo arm completed the 26-wk double-blind phase. Time to
                    relapse was described as longer for participants treated with aripiprazole
                    compared to those who were switched to placebo. Mean times to relapse were not
                    provided, but the hazard ratio for relapse was given as 0.52 (95%
                    confidence interval [CI] 0.30–0.91). When time to relapse was
                    partitioned into manic versus depressive relapse, the difference in overall time
                    to relapse was found to be driven primarily by an effect on manic relapse
                    (23% relapse rate on placebo versus 8% relapse rate on
                    aripiprazole). No differences in time to depressive relapse (13% versus
                    12%) or to mixed state relapse (6% versus 5%) were noted.
                    Keck and colleagues concluded that aripiprazole “was superior to placebo
                    in maintaining efficacy in patients with bipolar I disorder with a recent manic
                    or mixed episode who were stabilized and maintained on aripiprazole treatment
                    for 6 weeks” (p. 626) <xref ref-type="bibr" rid="pmed.1000434-Keck1">[39]</xref>.</p>
                <fig id="pmed-1000434-g003" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pmed.1000434.g003</object-id>
                    <label>Figure 3</label>
                    <caption>
                        <title>Keck study participant flow.</title>
                        <p>Participants had to complete the 6- to 18-wk stabilization phase before
                            they were eligible for randomization. After completion of the 26-wk
                            double-blind phase, participants were invited to continue in the 74-wk
                            extension phase.</p>
                    </caption>
                    <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1000434.g003" xlink:type="simple"/>
                </fig>
                <p>The extension phase of the Keck trial, published as a separate paper <xref ref-type="bibr" rid="pmed.1000434-Keck2">[40]</xref>, followed the
                    remaining participants over the subsequent 74 wk: 27 participants in the placebo
                    group (of the 28 who completed the double-blind phase) and 39 participants in
                    the aripiprazole group. The authors concluded: “Over a 100-week treatment
                    period, aripiprazole monotherapy was effective for relapse prevention in
                    patients who were initially stabilized on aripiprazole for 6 consecutive weeks,
                    and it maintained a good safety and tolerability profile” (p. 1480) <xref ref-type="bibr" rid="pmed.1000434-Keck2">[40]</xref>. Similar to
                    the data from the first 26 wk, time to manic relapse was reported to be longer
                    for the aripiprazole group (with no difference between groups in time to
                    depressive relapse).</p>
            </sec>
            <sec id="s3b">
                <title>Four Substantive Criticisms of the Keck Trial</title>
                <p>Although the Keck trial was the sole basis for aripiprazole receiving an
                    additional FDA-approved indication for the maintenance treatment of bipolar
                    disorder <xref ref-type="bibr" rid="pmed.1000434-US1">[29]</xref>, we
                    believe that reading the Keck trial as supporting the use of aripiprazole for
                    this indication is an overinterpretation of the trial's design and the data
                    it generated. First, the duration of the Keck trial was insufficient to
                    demonstrate prophylactic efficacy. Second, the double-blind phase of the Keck
                    trial was based on an enriched sample of patients who had already responded to
                    the medication during the stabilization phase, thereby limiting generalizability
                    of the trial's findings. Third, the randomized discontinuation design of
                    the Keck trial may conflate iatrogenic adverse effects of abrupt medication
                    discontinuation with the beneficial effects of short-term continuation
                    treatment. All of the putative benefit occurred during the double-blind phase of
                    the trial, and little improvement was gained during the extension phase. And
                    finally, the overall completion rate was 1.3%, requiring unrealistic
                    extrapolation to draw meaningful conclusions. Keck et al. <xref ref-type="bibr" rid="pmed.1000434-Keck1">[39]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Keck2">[40]</xref> mention lack of
                    generalizability as a potential limitation of the enrichment design, but they do
                    not discuss how these other limitations may have compromised the trial's
                    internal validity.</p>
                <p>The FDA's review of the Keck trial identified other substantive concerns,
                    including the fact that the <italic>p</italic>-value for the primary analysis
                    changed from 0.02 to 0.10 when the statistical reviewer excluded data from one
                    of the trial's two Mexican sites (where the relapse rate among participants
                    in the aripiprazole arm was lower than the other trial sites) <xref ref-type="bibr" rid="pmed.1000434-He1">[46]</xref>. While of
                    general concern, this and other issues identified by the FDA are unrelated to
                    our methodological critiques. All of these factors undercut even a cautious
                    interpretation of the Keck trial as supporting the use of aripiprazole for
                    maintenance treatment of bipolar disorder. Below we review each of these
                    criticisms in detail.</p>
                <sec id="s3b1">
                    <title>Insufficient duration to demonstrate prophylactic efficacy</title>
                    <p>In the open-label phase of the Keck trial, stability was defined by whether
                        or not a participant maintained YMRS and MADRS scores in the asymptomatic
                        range for at least 6 consecutive weeks. To meet this criterion, on average
                        the trial participants spent 89 d in the stabilization phase. Comparing
                        their own work to other randomized discontinuation studies of maintenance
                        treatment in bipolar disorder that required a shorter duration of stability
                            <xref ref-type="bibr" rid="pmed.1000434-Bowden1">[47]</xref>–<xref ref-type="bibr" rid="pmed.1000434-Calabrese1">[49]</xref>, Keck et al.
                        describe their stability criterion as “the most stringent criteria to
                        date to define stability” (p. 634) <xref ref-type="bibr" rid="pmed.1000434-Keck1">[39]</xref>. Intervention-arm
                        participants who had achieved stability on aripiprazole were then assigned
                        to continue with aripiprazole, and placebo-arm participants abruptly
                        switched to placebo, for the following 26 wk.</p>
                    <p>Contrary to the authors' claims, we argue here that, given the natural
                        history of bipolar disorder, the design of the Keck trial was unsuitable for
                        evaluating the efficacy of aripiprazole in the maintenance treatment of
                        bipolar disorder. The episodic nature of recurrent mania and depression
                        require investigators to randomize, enroll, and retain patients for a
                        duration sufficient to demonstrate maintenance and/or prophylactic efficacy.
                        While there is high interindividual variation, the median length of
                        untreated episodes has been reported to vary from 3–6 mo in clinical
                        trial settings and from 2–3 mo in epidemiological studies <xref ref-type="bibr" rid="pmed.1000434-Angst1">[50]</xref>, with
                        depressive episodes typically lasting longer than manic episodes <xref ref-type="bibr" rid="pmed.1000434-Goodwin2">[21]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Tohen3">[51]</xref>. Thus,
                        even if one does not accept the other methodological concerns we describe in
                        this paper, the Keck trial, with its stabilization criterion of 6 wk, could
                        at best be used to demonstrate a short-term benefit of continuation
                        treatment in preventing relapse of symptoms attributable to an ongoing acute
                        episode <xref ref-type="bibr" rid="pmed.1000434-Ghaemi4">[52]</xref>. Demonstration of maintenance efficacy in
                        preventing recurrence of mood episodes would require benefit to be shown at
                        least 6 mo after the acute phase. 6 mo has been traditionally recognized as
                        the point at which continuation treatment becomes maintenance treatment
                            <xref ref-type="bibr" rid="pmed.1000434-Storosum1">[10]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Ghaemi1">[11]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Goodwin1">[12]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Ghaemi4">[52]</xref>–<xref ref-type="bibr" rid="pmed.1000434-Quitkin2">[54]</xref>. Appropriately, the
                        clinical review contained in the supplemental NDA describes a meeting with
                        the study's sponsors in which the FDA's Division of
                        Neuropharmacological Drug Products “expressed that the duration of the
                        open-label stabilization phase defines duration of effect and noted that an
                        optimal study design would include a six month open-label stabilization
                        phase and randomized withdrawal of patient subgroups at specified
                        timepoints” (p. 9) <xref ref-type="bibr" rid="pmed.1000434-Prodruchny1">[55]</xref>. The leading
                        textbook in the field suggests an even more stringent threshold study
                        duration: “Because the natural history of bipolar disorder is for it
                        to recur, on average, every 16–18 months, true prophylaxis cannot be
                        evaluated in 6 or 12 months” (p. 801) <xref ref-type="bibr" rid="pmed.1000434-Goodwin2">[21]</xref>. Although somewhat
                        controversial, the idea that demonstration of true prophylactic efficacy
                        requires a study duration longer than that which has been typically utilized
                        has been supported by other leading researchers as well <xref ref-type="bibr" rid="pmed.1000434-Ghaemi1">[11]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Ghaemi4">[52]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Ghaemi5">[56]</xref>.</p>
                </sec>
                <sec id="s3b2">
                    <title>Limited generalizability due to the enriched sample</title>
                    <p>Only participants who had responded to aripiprazole in the stabilization
                        phase of the trial were included in the double-blind phase of the trial. Of
                        the 567 participants who entered the stabilization phase, only 206 completed
                        it. Some of the randomized participants received unblinded medication and
                        were therefore discontinued <xref ref-type="bibr" rid="pmed.1000434-US1">[29]</xref>, so the double-blind efficacy dataset consisted
                        of 161 participants. This means that 361 of the 567 (74%)
                        participants who entered the stabilization phase but dropped out were
                        excluded from randomization because of adverse events, lack of efficacy,
                        withdrawal of consent, and other reasons as detailed in the
                        publication—leaving behind a selected group of participants who had
                        responded favorably to aripiprazole in the stabilization phase to be
                        subsequently randomized. This design could have the effect of biasing the
                        trial's findings away from the null <xref ref-type="bibr" rid="pmed.1000434-Deshauer1">[57]</xref>, and, even in the
                        absence of such bias, the results from this enriched sample cannot be
                        generalized to the majority of persons diagnosed with bipolar disorder. This
                        limitation of the randomized discontinuation design has long been recognized
                        by drug trialists <xref ref-type="bibr" rid="pmed.1000434-Ghaemi1">[11]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Goodwin1">[12]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Ghaemi5">[56]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Smith1">[58]</xref>–<xref ref-type="bibr" rid="pmed.1000434-Stone1">[65]</xref> and is not dissimilar to
                        criticisms voiced about the first generation of randomized trials evaluating
                        the use of lithium for maintenance treatment in bipolar disorder, i.e., that
                        those study designs selected preferentially for lithium-responsive variants
                        of the disorder <xref ref-type="bibr" rid="pmed.1000434-Calabrese2">[66]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Calabrese3">[67]</xref>.</p>
                </sec>
                <sec id="s3b3">
                    <title>Possible conflation of iatrogenic effects with beneficial effects</title>
                    <p>The randomized discontinuation study design could explain the putatively
                        positive findings on preventing relapse even in the absence of a true drug
                        effect. In the Keck trial, the randomization sample was enriched with
                        participants who had already responded to aripiprazole in the stabilization
                        phase and were therefore more likely to experience an iatrogenic relapse of
                        symptoms when aripiprazole was abruptly discontinued in the double-blind
                        phase. Abrupt discontinuation, or even abrupt partial removal, of a drug
                        used for maintenance has long been known to provoke relapse in patients
                        diagnosed with bipolar disorder <xref ref-type="bibr" rid="pmed.1000434-Lapierre1">[68]</xref>–<xref ref-type="bibr" rid="pmed.1000434-Goodwin3">[77]</xref>. This
                        “bipolar rebound phenomenon” has been most often described for
                        lithium, but it has also been observed in the setting of abruptly withdrawn
                        antiepileptic <xref ref-type="bibr" rid="pmed.1000434-Franks1">[78]</xref>, antipsychotic <xref ref-type="bibr" rid="pmed.1000434-Healy1">[3]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Goodwin1">[12]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Tohen2">[48]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Ghaemi5">[56]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Franks1">[78]</xref>–<xref ref-type="bibr" rid="pmed.1000434-Baldessarini5">[80]</xref>,
                        and antidepressant medications <xref ref-type="bibr" rid="pmed.1000434-Greenhouse1">[59]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Baldessarini4">[75]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Franks1">[78]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Healy3">[81]</xref> administered to persons diagnosed with other mood
                        and psychotic disorders. For this reason, Geddes et al. specifically
                        excluded studies with a randomized discontinuation design from their
                        systematic review and meta-analysis of the long-term use of lithium in the
                        treatment of bipolar disorder <xref ref-type="bibr" rid="pmed.1000434-Geddes2">[82]</xref>.</p>
                    <p>Thus, if aripiprazole had no effect on preventing relapse, the Keck trial
                        might still be expected to show a higher relapse rate early in the
                        double-blind phase among participants assigned to the placebo arm (compared
                        to those assigned to the intervention arm), and then similar relapse rates
                        between study arms during the extension phase. This particular design
                        element appears to have substantially influenced the outcome of the Keck
                        trial, as is evident from a comparison of data from the 26-wk double-blind
                        phase with data from the 74-wk extension phase. During the 26-wk
                        double-blind phase, 19 out of 83 participants (23%) in the placebo
                        arm experienced a manic relapse, whereas only four (5%) did so in the
                        subsequent 74-wk extension phase.</p>
                    <p>When relapse data from the 74-wk extension phase are examined separately from
                        those from the first 26 wk (<xref ref-type="fig" rid="pmed-1000434-g003">Figure 3</xref>), only four participants in the placebo arm experienced
                        a relapse to mania, compared to 3 participants in the intervention arm
                        (4.8% versus 3.8%). This information is not explicitly
                        presented in either paper and can only be discerned by comparing the papers
                        side by side and calculating the differences by hand. <xref ref-type="fig" rid="pmed-1000434-g004">Figure 4</xref> in the 74-wk extension phase
                        publication (p. 1486) <xref ref-type="bibr" rid="pmed.1000434-Keck2">[40]</xref> shows that 28% of participants in the
                        placebo arm relapsed to mania over 100 wk of follow up. Given
                            <italic>n = </italic>83 in the placebo arm, this
                        suggests 23 participants in the placebo arm relapsed to mania over 100 wk of
                        follow up. Because 19 participants in the placebo arm relapsed to mania in
                        the first 26 wk (Figure 5 in the 26-wk double-blind phase publication
                        [p. 531] <xref ref-type="bibr" rid="pmed.1000434-Keck1">[39]</xref>), this means four participants relapsed to mania
                        during the 74-wk extension phase. We employed similar reasoning to calculate
                        the number of participants who relapsed to mania in the intervention arm, as
                        well as the number of participants who relapsed to depressive and mixed
                        states. Similar patterns are observed for relapse to depression and relapse
                        to mixed state for the placebo and aripiprazole arms. Thus, virtually all of
                        the reported placebo-aripiprazole difference in relapse occurred during the
                        first 26 wk of the trial.</p>
                    <fig id="pmed-1000434-g004" position="float">
                        <object-id pub-id-type="doi">10.1371/journal.pmed.1000434.g004</object-id>
                        <label>Figure 4</label>
                        <caption>
                            <title>Publications citing the Keck study.</title>
                            <p>These publications were identified using Web of Science(R) Science
                                Citation Index Expanded. Those that discussed the Keck study in
                                relation to the maintenance treatment of bipolar disorder were
                                evaluated on three quality indicators, as shown.</p>
                        </caption>
                        <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1000434.g004" xlink:type="simple"/>
                    </fig>
                </sec>
                <sec id="s3b4">
                    <title>Limitations of the low completion rate</title>
                    <p>Only seven of 39 (18%) aripiprazole-treated participants and five of
                        27 (19%) placebo-treated participants completed the 74-wk extension
                        phase. The low completion rate in the treatment arm is especially striking
                        given that only participants who had proven to be responders in the initial
                        stabilization phase were included in the double-blind and extension phases
                        and that the placebo group matched the aripiprazole group in terms of trial
                        completion. Out of the 633 participants who entered the trial, after
                        excluding the 83 who were switched to placebo, only seven
                        aripiprazole-treated participants completed the 100-wk trial, for a
                        completion rate among aripiprazole-treated participants of less than
                        1.3%. This is not explicitly noted anywhere in the paper <xref ref-type="bibr" rid="pmed.1000434-Keck2">[40]</xref>. Keck et
                        al. <xref ref-type="bibr" rid="pmed.1000434-Keck2">[40]</xref>
                        acknowledge that only 12 participants completed the trial, but the smaller
                        denominator used for comparison is the number of participants who entered
                        the 74-wk extension phase rather than all participants who entered the
                        trial.</p>
                    <p>We argue that drawing meaningful conclusions from a trial with an overall
                        completion rate of less than 1.3% is an inappropriate undertaking.
                        The completion rate substantially limits generalizability of the
                        trial's findings, as trial completers very likely were dissimilar to
                        the enrolled and/or randomized participant pools. The meaningful differences
                        between completers and noncompleters were demonstrated in a randomized trial
                        of divalproex versus lithium for relapse prevention in bipolar disorder
                            <xref ref-type="bibr" rid="pmed.1000434-Bowden2">[83]</xref>:
                        participants who completed the trial had milder symptoms at baseline and a
                        less severe lifetime illness course <xref ref-type="bibr" rid="pmed.1000434-Bowden3">[84]</xref>. Keck et al. identify
                        the low completion rate in the extension phase as a potential limitation but
                        appeal to the low completion rates observed in other maintenance trials
                            <xref ref-type="bibr" rid="pmed.1000434-Bowden1">[47]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Tohen2">[48]</xref> to support the generalizability of their results.
                        In contrast, we view the similar completion rates observed in other
                        long-term studies as similarly raising concerns about how to draw inferences
                        from these trials to inform routine clinical practice. Still, we observe
                        that other investigators have successfully implemented long-term studies in
                        this patient population with greater rates of completion: for example,
                        earlier studies of lithium in the treatment of affective disorders
                        demonstrated completion rates of 92.9% (26/28) <xref ref-type="bibr" rid="pmed.1000434-Coppen1">[85]</xref> and 73.2%
                        (74/101) <xref ref-type="bibr" rid="pmed.1000434-Prien1">[86]</xref> among lithium-treated participants.</p>
                </sec>
            </sec>
            <sec id="s3c">
                <title>Impact of the Keck Trial on the Literature</title>
                <p>Our citation search protocol identified 80 articles that cited the results from
                    the 26-wk double-blind phase <xref ref-type="bibr" rid="pmed.1000434-Keck1">[39]</xref> and 48 articles that cited the results of the 74-wk
                    extension phase <xref ref-type="bibr" rid="pmed.1000434-Keck2">[40]</xref>. After eliminating duplicates, the two publications
                    from the Keck trial garnered 104 subsequent citations in total. Of these citing
                    articles, 24 did not contain any mention of the Keck trial in relation to
                    long-term or maintenance treatment of bipolar disorder and were excluded from
                    further analysis (<xref ref-type="fig" rid="pmed-1000434-g004">Figure 4</xref>).
                    Double-coding revealed a high degree of inter-rater agreement on the quality
                    assessment measures. There was 100% agreement on whether the publications
                    were classified as mentioning aripiprazole for maintenance treatment. Among the
                    double-coded publications mentioning maintenance treatment, there was
                    100% agreement on whether quantitative data and limitations were
                    mentioned. There was one disagreement about whether adverse events were
                    mentioned, yielding a kappa coefficient of 0.75 (95% CI 0.05–0.95).
                    The overall kappa coefficient was 0.95 (95% CI 0.73–0.99).</p>
                <p>Of the 80 articles that cited the Keck trial in reference to maintenance
                    treatment of bipolar disorder, only 20 (25%) presented any quantitative
                    data from the Keck trial; the remainder reported qualitative statements only
                    (e.g., “Aripiprazole significantly delayed the time to relapse into a new
                    mood episode in patients with bipolar I disorder over both 26 and 100 weeks of
                    treatment.” <xref ref-type="bibr" rid="pmed.1000434-Kemp1">[87]</xref>). 24 publications (30%) mentioned any of the
                    adverse events reported in the trial. Only four (5%) made any mention of
                    study limitations.</p>
                <p>Among the articles identified through our citation search protocol were eight
                    literature reviews <xref ref-type="bibr" rid="pmed.1000434-Fountoulakis1">[88]</xref>–<xref ref-type="bibr" rid="pmed.1000434-Ulusahin1">[95]</xref> and three bipolar
                    treatment guidelines <xref ref-type="bibr" rid="pmed.1000434-Suppes1">[15]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Yatham1">[96]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Goodwin4">[97]</xref> that specifically discussed the use of aripiprazole
                    in the treatment of bipolar disorder. Because review articles and treatment
                    guidelines can be particularly influential in shaping policy and prescribing
                    behavior, we chose to highlight these in our discussion (<xref ref-type="table" rid="pmed-1000434-t001">Table 1</xref>). The evidence summaries employed the
                    methodologies of consensus panel (<italic>n = </italic>3),
                    narrative review (<italic>n = </italic>6), or systematic
                    review (<italic>n = </italic>2). Ten of the 11 reviews and
                    treatment guidelines contained a financial disclosure related to Bristol-Myers
                    Squibb.</p>
                <table-wrap id="pmed-1000434-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1000434.t001</object-id><label>Table 1</label><caption>
                        <title>Treatment guidelines and reviews of aripiprazole for the treatment of
                            bipolar disorder.</title>
                    </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pmed-1000434-t001-1" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1000434.t001" xlink:type="simple"/><table>
                        <colgroup span="1">
                            <col align="left" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                        </colgroup>
                        <thead>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Author, Year, Country</td>
                                <td align="left" colspan="1" rowspan="1">Financial Disclosure Related to Bristol-Myers
                                    Squibb</td>
                                <td align="left" colspan="1" rowspan="1">Methods</td>
                                <td align="left" colspan="3" rowspan="1">Quality Indicators<xref ref-type="table-fn" rid="nt101">a</xref></td>
                                <td align="left" colspan="1" rowspan="1">Narrative Recommendation</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">A</td>
                                <td align="left" colspan="1" rowspan="1">B</td>
                                <td align="left" colspan="1" rowspan="1">C</td>
                                <td align="left" colspan="1" rowspan="1"/>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Goodwin, 2009, Great Britain <xref ref-type="bibr" rid="pmed.1000434-Goodwin4">[97]</xref></td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">Consensus panel</td>
                                <td align="left" colspan="1" rowspan="1">No</td>
                                <td align="left" colspan="1" rowspan="1">No</td>
                                <td align="left" colspan="1" rowspan="1">No</td>
                                <td align="left" colspan="1" rowspan="1">“Aripiprazole was more effective than placebo
                                    after acute and continuation treatment of mania with
                                    aripiprazole: no effect on depression was discernable. Acute
                                    withdrawal of the active agent did not produce an excess of
                                    early relapse in this study.” <bold>(positive)</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Yatham, 2009, Canada <xref ref-type="bibr" rid="pmed.1000434-Yatham1">[96]</xref></td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">Consensus panel</td>
                                <td align="left" colspan="1" rowspan="1">No</td>
                                <td align="left" colspan="1" rowspan="1">No</td>
                                <td align="left" colspan="1" rowspan="1">No</td>
                                <td align="left" colspan="1" rowspan="1">“Given that efficacy was shown primarily for
                                    mania, aripiprazole is included as a first-line maintenance
                                    treatment for bipolar disorder for the treatment and prevention
                                    of mania.” <bold>(positive)</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Suppes, 2005, United States <xref ref-type="bibr" rid="pmed.1000434-Suppes1">[15]</xref></td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">Consensus panel</td>
                                <td align="left" colspan="1" rowspan="1">No</td>
                                <td align="left" colspan="1" rowspan="1">No</td>
                                <td align="left" colspan="1" rowspan="1">No</td>
                                <td align="left" colspan="1" rowspan="1">“Aripiprazole is recommended based on a
                                    randomized, double-blind, placebo-controlled, 6-month
                                    maintenance study in which patients received open-label
                                    aripiprazole until stable, then were randomized to either
                                    placebo or aripiprazole for the 6-month follow-up.”
                                        <bold>(positive)</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Garcia-Amador, 2006, Spain <xref ref-type="bibr" rid="pmed.1000434-GarciaAmador1">[93]</xref></td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">Narrative review</td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">No</td>
                                <td align="left" colspan="1" rowspan="1">“These data support the decision by the US
                                    FDA to approve aripiprazole for the maintenance treatment of
                                    bipolar patients, beyond the treatment of acute mania.”
                                        <bold>(positive)</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">McIntyre, 2007, Canada <xref ref-type="bibr" rid="pmed.1000434-McIntyre2">[91]</xref></td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">Narrative review</td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">No</td>
                                <td align="left" colspan="1" rowspan="1">“Aripiprazole is established as being
                                    efficacious in acute mania and for the prevention of manic
                                    relapse in BD. Aripiprazole efficacy is confirmed on primary and
                                    secondary efficacy parameters.”
                                    <bold>(positive)</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Fagiolini, 2008, United States <xref ref-type="bibr" rid="pmed.1000434-Fagiolini1">[94]</xref></td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">Narrative review</td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">No</td>
                                <td align="left" colspan="1" rowspan="1">“This 100-week study showed a significantly
                                    longer time to relapse with aripiprazole when compared with
                                    placebo.” <bold>(positive)</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">McIntyre, 2007, Canada <xref ref-type="bibr" rid="pmed.1000434-McIntyre1">[90]</xref></td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">Narrative review</td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">No</td>
                                <td align="left" colspan="1" rowspan="1">“A single, randomized, double-blind, parallel
                                    group, placebo-controlled study reported on the safety and
                                    efficacy of aripiprazole in preventing relapse of a mood episode
                                    in recently manic or mixed episode patients with bipolar I
                                    disorder.” <bold>(positive)</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Ulusahin, 2008, Turkey <xref ref-type="bibr" rid="pmed.1000434-Ulusahin1">[95]</xref></td>
                                <td align="left" colspan="1" rowspan="1">None disclosed</td>
                                <td align="left" colspan="1" rowspan="1">Narrative review</td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">No</td>
                                <td align="left" colspan="1" rowspan="1">“One double-blind, randomized, placebo
                                    controlled clinical trial of 100-week aripiprazole monotherapy,
                                    which is the longest clinical trial among the trials conducted
                                    in bipolar disorder among the second-generation antipsychotics,
                                    showed that aripiprazole was effective for relapse prevention in
                                    bipolar patients.” <bold>(positive)</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Muzina, 2009, United States <xref ref-type="bibr" rid="pmed.1000434-Muzina2">[89]</xref></td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">Narrative review</td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">No</td>
                                <td align="left" colspan="1" rowspan="1">“The results from a 100-week study of
                                    aripiprazole for the prevention of bipolar I episodes represent
                                    the longest maintenance study since early lithium trials and
                                    support the use of aripiprazole as maintenance treatment,
                                    primarily against manic relapses.”
                                    <bold>(positive)</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Fountoulakis, 2009, Greece <xref ref-type="bibr" rid="pmed.1000434-Fountoulakis1">[88]</xref></td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">Systematic review</td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">“Recent reviews suggest that aripiprazole is
                                    efficacious in acute mania and in the maintenance treatment of
                                    bipolar disorder, with a favourable safety and tolerability
                                    profile, with minimal propensity for clinically significant
                                    weight gain and metabolic disruption.”
                                        <bold>(positive)</bold></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">McIntyre, 2010, Canada <xref ref-type="bibr" rid="pmed.1000434-McIntyre3">[92]</xref></td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">Systematic review</td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">Yes</td>
                                <td align="left" colspan="1" rowspan="1">“The available evidence supports the efficacy
                                    and tolerability of aripiprazole in the maintenance treatment of
                                    bipolar disorder.” <bold>(positive)</bold></td>
                            </tr>
                        </tbody>
                    </table></alternatives><table-wrap-foot>
                        <fn id="nt101">
                            <label>a</label>
                            <p>A, reported any quantitative data; B, reported any adverse events; C,
                                reported any study limitations.</p>
                        </fn>
                        <fn id="nt102">
                            <label/>
                            <p>BD, bipolar disorder.</p>
                        </fn>
                    </table-wrap-foot></table-wrap>
                <p>Overall, the eight reviews were favorable in their assessment as to the putative
                    efficacy of aripiprazole in the maintenance treatment of bipolar disorder.
                    Solely on the basis of the results of the Keck trial, the Texas Medication
                    Algorithm Project update listed aripiprazole as having “level 2”
                    evidence (out of five levels of quality, with level 1 being the highest-quality)
                    for maintenance treatment of bipolar disorder <xref ref-type="bibr" rid="pmed.1000434-Suppes1">[15]</xref>. The Canadian Network for
                    Mood and Anxiety Treatments and International Society for Bipolar Disorders
                    recommended aripiprazole as first-line maintenance treatment of bipolar
                    disorder, although it is noted that this is “mainly for preventing
                    mania” (p. 235) <xref ref-type="bibr" rid="pmed.1000434-Yatham1">[96]</xref>. This treatment recommendation was based on the Keck
                    trial, along with a 30-wk pediatric bipolar trial that has only been published
                    in abstract form <xref ref-type="bibr" rid="pmed.1000434-Forbes1">[98]</xref>. The British Association for Psychopharmacology (BAP)
                    based its positive endorsement of aripiprazole for relapse prevention solely on
                    the Keck trial <xref ref-type="bibr" rid="pmed.1000434-Goodwin4">[97]</xref>. Contrary to the criticisms we described earlier, the
                    BAP guidelines note, “Acute withdrawal of the active agent did not produce
                    an excess of early relapse in this study” (p. 26).</p>
            </sec>
        </sec>
        <sec id="s4">
            <title>Discussion</title>
            <p>Our evaluation of the evidence base supporting the use of aripiprazole for the
                maintenance treatment of bipolar disorder reveals that the justification for this
                practice relies on the results from a single trial by Keck and colleagues published
                in two peer-reviewed journal articles <xref ref-type="bibr" rid="pmed.1000434-Keck1">[39]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Keck2">[40]</xref>. The methodology and reporting of the Keck trial are such
                that the results cannot be generalized to inform the treatment of most patients with
                bipolar disorder. Published interpretations of the data notwithstanding, in our
                opinion the Keck trial does not provide data to support the use of aripiprazole in
                the maintenance treatment of bipolar disorder. This lack of robust evidence of
                benefit should be weighed against the potential for long-term harms that have been
                described with other antipsychotic medications <xref ref-type="bibr" rid="pmed.1000434-Healy1">[3]</xref> and adverse events related to
                aripiprazole use, including tremor, akathisia, and significant weight gain <xref ref-type="bibr" rid="pmed.1000434-Keck1">[39]</xref>. Our concern
                about the critical imitations in this trial is further accentuated by the apparent
                widespread use of aripiprazole as a first-line agent for the maintenance treatment
                of bipolar disorder <xref ref-type="bibr" rid="pmed.1000434-Chow1">[31]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Diak1">[32]</xref>.</p>
            <p>Although we appreciate that the unique clinical features of bipolar disorder make
                controlled study extremely difficult <xref ref-type="bibr" rid="pmed.1000434-Calabrese3">[67]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Bowden3">[84]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Baldessarini6">[99]</xref>–<xref ref-type="bibr" rid="pmed.1000434-Prien2">[103]</xref>, many of the
                weaknesses we document stem from the use of the randomized discontinuation design.
                Further study is needed in order to determine whether the problems described in this
                particular case are also more widely applicable to other continuation or maintenance
                treatment studies in bipolar disorder. We find unpersuasive the argument that a
                randomized discontinuation study such as this is valuable because it reflects common
                clinical practice <xref ref-type="bibr" rid="pmed.1000434-Tohen4">[104]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Swann1">[105]</xref>. The two-arm, parallel randomized controlled trial may
                yield information that is more clinically useful than the discontinuation design.
                Under the parallel design, data from all participants (not just those who
                demonstrated an acute response) would contribute to our understanding of the
                drug's short- and long-term efficacy: one of two medications (or placebo) would
                be given to participants in the acute phase, and they would be followed throughout
                the continuation and maintenance phases (and beyond) to document response to
                treatment. (This study design, as well as the other study designs we describe,
                clearly could be used to study nonpharmacological treatments, including
                evidence-based psychotherapies. However, because this paper has emphasized
                discussion about pharmacologic treatments, we use the phrase
                “medication” for simplicity.) A two-arm, parallel randomized controlled
                trial of sufficient duration would directly answer the substantive research
                question, “Does aripiprazole treat symptoms to remission and prevent recurrent
                episodes when given to patients diagnosed with bipolar disorder presenting in a
                manic or mixed state?” This is clearly different from the question answered by
                the discontinuation design, “Among patients diagnosed with bipolar presenting
                in a manic or mixed state who have achieved a reasonable symptomatic improvement
                after being given aripiprazole, should aripiprazole be continued to maintain the
                initial improvement?” <xref ref-type="bibr" rid="pmed.1000434-Mallinckrodt1">[106]</xref>.</p>
            <p>The primary disadvantage of the parallel design is that a greater proportion of
                (acutely ill) study participants would be subjected to placebo for the full duration
                of the trial, exactly the ethical issue that the discontinuation design was intended
                to address <xref ref-type="bibr" rid="pmed.1000434-Amery1">[107]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Temple1">[108]</xref>. Keck et al. <xref ref-type="bibr" rid="pmed.1000434-Keck1">[39]</xref> stated that they sought to
                minimize the extent to which stabilized participants were administered placebo. Yet
                their study could have been modified to diminish its exposure to the weaknesses that
                we have described above. First, the duration of stability required prior to
                randomization could be lengthened. One likely cost of this design modification is
                that the proportion of participants actually randomized would decrease further <xref ref-type="bibr" rid="pmed.1000434-Peselow1">[109]</xref>. A second
                modification would be to gradually taper the discontinuation of medication among
                participants randomized to receive placebo. In previously published randomized
                discontinuation studies, medications administered during the open-label phase were
                tapered over a period of 2 to 3 wk rather than abruptly discontinued <xref ref-type="bibr" rid="pmed.1000434-Bowden1">[47]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Bowden2">[83]</xref>. Greenhouse et
                al. <xref ref-type="bibr" rid="pmed.1000434-Greenhouse1">[59]</xref>
                suggest implementing the taper over several months.</p>
            <p>Aside from these modifications to the parallel design, other alternatives have been
                suggested. Greenhouse et al. <xref ref-type="bibr" rid="pmed.1000434-Greenhouse1">[59]</xref> proposed an alternative randomization scheme in which
                study participants are randomized to one of six treatment strategies. In the acute
                phase of treatment, study participants would receive one of two medications. In the
                maintenance phase of treatment, study participants would either remain on the
                medication initiated during the acute phase, be switched (gradually) to the
                alternative medication, or be switched (gradually) to placebo. This innovative study
                design would address the substantive research question, “Which treatment
                strategy is better in controlling and preventing the recurrence of
                depression?” (p. 318) <xref ref-type="bibr" rid="pmed.1000434-Greenhouse1">[59]</xref>. A pure prophylactic design has also been recommended
                    <xref ref-type="bibr" rid="pmed.1000434-Storosum1">[10]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Goodwin1">[12]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Goodwin5">[100]</xref>, in which
                patients previously diagnosed with a recurrent mood disorder would be enrolled
                during a medication-free remission period. Then, while participants are in
                remission, they would be offered one of two medications (or placebo). All
                participants would be followed in the study for a prespecified duration, and the
                treatment arms would be compared in terms of time to recurrence of a mood episode.
                This design would avoid the previously described error of possibly conflating
                beneficial treatment effects with iatrogenic adverse effects of abrupt medication
                discontinuation. However, as noted by Goodwin, Whitman, and Ghaemi <xref ref-type="bibr" rid="pmed.1000434-Goodwin1">[12]</xref>, the failure
                of the divalproex study by Bowden et al. <xref ref-type="bibr" rid="pmed.1000434-Bowden2">[83]</xref> was partly attributed to its
                enrollment of participants with low severity of illness <xref ref-type="bibr" rid="pmed.1000434-Bowden3">[84]</xref>—and it was the last study
                to utilize the lithium-era prophylaxis design.</p>
            <p>We recognize that the proposed study designs will be regarded by some as too costly
                or infeasible. Although some have suggested that a study with selected limitations
                may be useful in guiding clinical practice <xref ref-type="bibr" rid="pmed.1000434-Tohen4">[104]</xref>, we would disagree with this
                argument. The current “anti-Hippocratic” state of psychopharmacological
                practice described by Ghaemi <xref ref-type="bibr" rid="pmed.1000434-Ghaemi5">[56]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Ghaemi6">[110]</xref> raises questions about the extent to which research with
                substantive limitations is appropriately interpreted with conservative
                sensibilities. These concerns are borne out in our data. Thomson Reuters Essential
                Science Indicators(SM) places the 26-wk double-blind phase publication in the top
                1%, and the 74-wk extension phase publication in the top
                1%–2%, of papers published in the fields of psychiatry and
                psychology. Thus, by our conservative estimates, the Keck trial could be regarded as
                relatively influential. More importantly, we found that the Keck trial was cited
                uncritically by a subsequent generation of authors, through treatment guidelines,
                reviews, and other publications. All failed to note the consequences of abrupt and
                premature discontinuation of antimanic medication, especially during the vulnerable
                continuation period. The uncritical manner in which the Keck trial has been cited is
                reminiscent of the “echo chamber” effect described by Carey et al. <xref ref-type="bibr" rid="pmed.1000434-Carey1">[111]</xref> in their
                assessment of the now-discredited use of gabapentin in the treatment of bipolar
                disorder. Although the analogy is somewhat limited as there were no reportedly
                positive double-blind trials examining the use of gabapentin for this indication, we
                document a similar pattern of uncritical citations of the primary evidence regarding
                aripiprazole in the maintenance treatment of bipolar disorder.</p>
            <p>Of further concern regarding the uncritical citation of the Keck trial's claims
                is that ten of the 11 treatment guidelines and review articles in our sample
                contained a financial disclosure related to the drug's manufacturer,
                Bristol-Myers Squibb Co. Financial conflicts of interest are highly prevalent across
                a wide range of medical subfields <xref ref-type="bibr" rid="pmed.1000434-Choudhry1">[112]</xref>, and while they are known to be associated with
                recommendations in review articles <xref ref-type="bibr" rid="pmed.1000434-Stelfox1">[113]</xref>, there is no systematic research documenting their
                influence on clinical practice guideline recommendations <xref ref-type="bibr" rid="pmed.1000434-Abramson1">[114]</xref>. However, financial
                conflicts of interest have been found to be associated with biased reporting of
                outcomes in randomized trials <xref ref-type="bibr" rid="pmed.1000434-Rising1">[115]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Lexchin1">[116]</xref>, which serve as the evidence upon which treatment
                guideline recommendations are based.</p>
            <p>In summary, we provide here a critical appraisal of the available evidence regarding
                the use of aripiprazole for the maintenance treatment of bipolar disorder. The
                available evidence consists of a single trial by Keck et al. <xref ref-type="bibr" rid="pmed.1000434-Keck1">[39]</xref>,<xref ref-type="bibr" rid="pmed.1000434-Keck2">[40]</xref>, which is subject to several
                substantive methodological limitations but has nonetheless been cited uncritically
                in the ensuing scientific literature. Several alternative modifications or study
                designs may improve the probability of generating more useful data from studies in
                this vulnerable patient population to inform the treatment of similar patients in
                the future. We are concerned that the publication and apparently uncritical
                acceptance of this trial may be diverting patients away from more effective
                treatments.</p>
        </sec>
        <sec id="s5">
            <title>Supporting Information</title>
            <supplementary-material id="pmed.1000434.s001" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pmed.1000434.s001" xlink:type="simple">
                <label>Table S1</label>
                <caption>
                    <p>Published studies excluded from review. These five published studies were not
                        included in the review because they were open-label, examined the use of
                        aripiprazole as adjunctive treatment or for acute mania, or lacked
                        sufficient duration.</p>
                    <p>(0.03 MB DOC)</p>
                </caption>
            </supplementary-material>
            <supplementary-material id="pmed.1000434.s002" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pmed.1000434.s002" xlink:type="simple">
                <label>Table S2</label>
                <caption>
                    <p>Clinical trial registry studies excluded from review. These 12 studies were
                        not included in the review because they were open-label, examined the use of
                        aripiprazole as adjunctive treatment or for acute mania, or lacked
                        sufficient duration.</p>
                    <p>(0.04 MB DOC)</p>
                </caption>
            </supplementary-material>
            <supplementary-material id="pmed.1000434.s003" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pmed.1000434.s003" xlink:type="simple">
                <label>Text S1</label>
                <caption>
                    <p>Approval package for: 21-436/S-005 &amp; S-008 &amp; 21-713/S-003. Washington
                        (D.C.): Center for Drug Evaluation and Research, U.S. Food and Drug
                        Administration; 2005. This supplemental New Drug Application (sNDA), which
                        provides for the use of aripiprazole as maintenance therapy in bipolar I
                        disorder, was obtained through a U.S. Freedom of Information Act
                        request.</p>
                    <p>(4.92 MB PDF)</p>
                </caption>
            </supplementary-material>
        </sec>
    </body>
    <back>
        <ack>
            <p>The authors thank Anne Ludvik of the library service at the San Francisco Veterans
                Affairs Medical Center, for help in crafting the evidence search protocols and the
                citation search protocol; five reviewers, for helpful suggestions; and Tom Zamojcin
                at Thomson Reuters, for providing the Essential Science Indicators data.</p>
        </ack>
        <ref-list>
            <title>References</title>
            <ref id="pmed.1000434-Tohen1">
                <label>1</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Tohen</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Jacobs</surname>
                            <given-names>TG</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Feldman</surname>
                            <given-names>PD</given-names>
                        </name>
                    </person-group>
                    <year>2000</year>
                    <article-title>Onset of action of antipsychotics in the treatment of
                        mania.</article-title>
                    <source>Bipolar Disord</source>
                    <volume>2</volume>
                    <fpage>261</fpage>
                    <lpage>268</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Wolfsperger1">
                <label>2</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Wolfsperger</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Greil</surname>
                            <given-names>W</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Rossler</surname>
                            <given-names>W</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Grohmann</surname>
                            <given-names>R</given-names>
                        </name>
                    </person-group>
                    <year>2007</year>
                    <article-title>Pharmacological treatment of acute mania in psychiatric
                        in-patients between 1994 and 2004.</article-title>
                    <source>J Affect Disord</source>
                    <volume>99</volume>
                    <fpage>9</fpage>
                    <lpage>17</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Healy1">
                <label>3</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Healy</surname>
                            <given-names>D</given-names>
                        </name>
                    </person-group>
                    <year>2006</year>
                    <article-title>The latest mania: selling bipolar disorder.</article-title>
                    <source>PLoS Med</source>
                    <volume>3</volume>
                    <fpage>e185</fpage>
                    <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0030185" xlink:type="simple">10.1371/journal.pmed.0030185</ext-link></comment>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Malhi1">
                <label>4</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Malhi</surname>
                            <given-names>GS</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Adams</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Berk</surname>
                            <given-names>M</given-names>
                        </name>
                    </person-group>
                    <year>2009</year>
                    <article-title>Medicating mood with maintenance in mind: bipolar depression
                        pharmacotherapy.</article-title>
                    <source>Bipolar Disord</source>
                    <volume>11</volume>
                    <supplement>Suppl 2</supplement>
                    <fpage>55</fpage>
                    <lpage>76</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Spielmans1">
                <label>5</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Spielmans</surname>
                            <given-names>GI</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Parry</surname>
                            <given-names>PI</given-names>
                        </name>
                    </person-group>
                    <year>2010</year>
                    <article-title>From evidence-based medicine to marketing-based medicine:
                        evidence from internal industry documents.</article-title>
                    <source>J Bioeth Inquiry</source>
                    <volume>7</volume>
                    <fpage>13</fpage>
                    <lpage>29</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Healy2">
                <label>6</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Healy</surname>
                            <given-names>D</given-names>
                        </name>
                    </person-group>
                    <year>2010</year>
                    <article-title>From mania to bipolar disorder.</article-title>
                    <person-group person-group-type="editor">
                        <name name-style="western">
                            <surname>Yatham</surname>
                            <given-names>LN</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Maj</surname>
                            <given-names>M</given-names>
                        </name>
                    </person-group>
                    <source>Bipolar disorder: clinical and neurobiological foundations</source>
                    <publisher-loc>Oxford</publisher-loc>
                    <publisher-name>John Wiley &amp; Sons, Ltd</publisher-name>
                    <fpage>1</fpage>
                    <lpage>7</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Mark1">
                <label>7</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Mark</surname>
                            <given-names>TL</given-names>
                        </name>
                    </person-group>
                    <year>2010</year>
                    <article-title>For what diagnoses are psychotropic medications being
                        prescribed?: a nationally representative survey of
                        physicians.</article-title>
                    <source>CNS Drugs</source>
                    <volume>24</volume>
                    <fpage>319</fpage>
                    <lpage>326</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Depp1">
                <label>8</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Depp</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ojeda</surname>
                            <given-names>VD</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Mastin</surname>
                            <given-names>W</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Unutzer</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Gilmer</surname>
                            <given-names>TP</given-names>
                        </name>
                    </person-group>
                    <year>2008</year>
                    <article-title>Trends in use of antipsychotics and mood stabilizers among
                        Medicaid beneficiaries with bipolar disorder, 2001-2004.</article-title>
                    <source>Psychiatr Serv</source>
                    <volume>59</volume>
                    <fpage>1169</fpage>
                    <lpage>1174</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Frank1">
                <label>9</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Frank</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Prien</surname>
                            <given-names>RF</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Jarrett</surname>
                            <given-names>RB</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Keller</surname>
                            <given-names>MB</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kupfer</surname>
                            <given-names>DJ</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>1991</year>
                    <article-title>Conceptualization and rationale for consensus definitions of
                        terms in major depressive disorder. Remission, recovery, relapse, and
                        recurrence.</article-title>
                    <source>Arch Gen Psychiatry</source>
                    <volume>48</volume>
                    <fpage>851</fpage>
                    <lpage>855</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Storosum1">
                <label>10</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Storosum</surname>
                            <given-names>JG</given-names>
                        </name>
                        <name name-style="western">
                            <surname>van Zwieten</surname>
                            <given-names>BJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Vermeulen</surname>
                            <given-names>HD</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Wohlfarth</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>van den Brink</surname>
                            <given-names>W</given-names>
                        </name>
                    </person-group>
                    <year>2001</year>
                    <article-title>Relapse and recurrence prevention in major depression: a critical
                        review of placebo-controlled efficacy studies with special emphasis on
                        methodological issues.</article-title>
                    <source>Eur Psychiatry</source>
                    <volume>16</volume>
                    <fpage>327</fpage>
                    <lpage>335</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Ghaemi1">
                <label>11</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Ghaemi</surname>
                            <given-names>SN</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Pardo</surname>
                            <given-names>TB</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hsu</surname>
                            <given-names>DJ</given-names>
                        </name>
                    </person-group>
                    <year>2004</year>
                    <article-title>Strategies for preventing the recurrence of bipolar
                        disorder.</article-title>
                    <source>J Clin Psychiatry</source>
                    <volume>65</volume>
                    <supplement>Suppl 10</supplement>
                    <fpage>16</fpage>
                    <lpage>23</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Goodwin1">
                <label>12</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Goodwin</surname>
                            <given-names>FK</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Whitham</surname>
                            <given-names>EA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ghaemi</surname>
                            <given-names>SN</given-names>
                        </name>
                    </person-group>
                    <year>2011</year>
                    <article-title>Relapse prevention in bipolar disorder: have any neuroleptics
                        been shown to be ‘mood stabilizers’?</article-title>
                    <publisher-name>CNS Drugs</publisher-name>
                    <comment>In press</comment>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Sachs1">
                <label>13</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Sachs</surname>
                            <given-names>GS</given-names>
                        </name>
                    </person-group>
                    <year>1996</year>
                    <article-title>Bipolar mood disorder: practical strategies for acute and
                        maintenance phase treatment.</article-title>
                    <source>J Clin Psychopharmacol</source>
                    <volume>16</volume>
                    <fpage>32S</fpage>
                    <lpage>47S</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Sachs2">
                <label>14</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Sachs</surname>
                            <given-names>GS</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Printz</surname>
                            <given-names>DJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kahn</surname>
                            <given-names>DA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Carpenter</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Docherty</surname>
                            <given-names>JP</given-names>
                        </name>
                    </person-group>
                    <year>2000</year>
                    <article-title>The expert consensus guideline series: medication treatment of
                        bipolar disorder 2000.</article-title>
                    <publisher-name>Postgrad Med Spec No</publisher-name>
                    <fpage>1</fpage>
                    <lpage>104</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Suppes1">
                <label>15</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Suppes</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Dennehy</surname>
                            <given-names>EB</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hirschfeld</surname>
                            <given-names>RM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Altshuler</surname>
                            <given-names>LL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bowden</surname>
                            <given-names>CL</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2005</year>
                    <article-title>The Texas implementation of medication algorithms: update to the
                        algorithms for treatment of bipolar I disorder.</article-title>
                    <source>J Clin Psychiatry</source>
                    <volume>66</volume>
                    <fpage>870</fpage>
                    <lpage>886</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Perlis1">
                <label>16</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Perlis</surname>
                            <given-names>RH</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Welge</surname>
                            <given-names>JA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Vornik</surname>
                            <given-names>LA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hirschfeld</surname>
                            <given-names>RM</given-names>
                        </name>
                    </person-group>
                    <collab xlink:type="simple">Keck PE Jr.</collab>
                    <year>2006</year>
                    <article-title>Atypical antipsychotics in the treatment of mania: a
                        meta-analysis of randomized, placebo-controlled trials.</article-title>
                    <source>J Clin Psychiatry</source>
                    <volume>67</volume>
                    <fpage>509</fpage>
                    <lpage>516</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Scherk1">
                <label>17</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Scherk</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Pajonk</surname>
                            <given-names>FG</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Leucht</surname>
                            <given-names>S</given-names>
                        </name>
                    </person-group>
                    <year>2007</year>
                    <article-title>Second-generation antipsychotic agents in the treatment of acute
                        mania: a systematic review and meta-analysis of randomized controlled
                        trials.</article-title>
                    <source>Arch Gen Psychiatry</source>
                    <volume>64</volume>
                    <fpage>442</fpage>
                    <lpage>455</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Vieta1">
                <label>18</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Vieta</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sanchez-Moreno</surname>
                            <given-names>J</given-names>
                        </name>
                    </person-group>
                    <year>2008</year>
                    <article-title>Acute and long-term treatment of mania.</article-title>
                    <source>Dialogues Clin Neurosci</source>
                    <volume>10</volume>
                    <fpage>165</fpage>
                    <lpage>179</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Bauer1">
                <label>19</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Bauer</surname>
                            <given-names>MS</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Mitchner</surname>
                            <given-names>L</given-names>
                        </name>
                    </person-group>
                    <year>2004</year>
                    <article-title>What is a “mood stabilizer”? An evidence-based
                        response.</article-title>
                    <source>Am J Psychiatry</source>
                    <volume>161</volume>
                    <fpage>3</fpage>
                    <lpage>18</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Ghaemi2">
                <label>20</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Ghaemi</surname>
                            <given-names>SN</given-names>
                        </name>
                    </person-group>
                    <year>2001</year>
                    <article-title>On defining ‘mood stabilizer’.</article-title>
                    <source>Bipolar Disord</source>
                    <volume>3</volume>
                    <fpage>154</fpage>
                    <lpage>158</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Goodwin2">
                <label>21</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Goodwin</surname>
                            <given-names>FK</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Jamison</surname>
                            <given-names>KR</given-names>
                        </name>
                    </person-group>
                    <year>2007</year>
                    <article-title>Manic-depressive illness: bipolar disorders and recurrent
                        depression.</article-title>
                    <publisher-loc>New York</publisher-loc>
                    <publisher-name>Oxford University Press</publisher-name>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Suppes2">
                <label>22</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Suppes</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Vieta</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Liu</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Brecher</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Paulsson</surname>
                            <given-names>B</given-names>
                        </name>
                    </person-group>
                    <year>2009</year>
                    <article-title>Maintenance treatment for patients with bipolar I disorder:
                        results from a north american study of quetiapine in combination with
                        lithium or divalproex (trial 127).</article-title>
                    <source>Am J Psychiatry</source>
                    <volume>166</volume>
                    <fpage>476</fpage>
                    <lpage>488</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Geddes1">
                <label>23</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Geddes</surname>
                            <given-names>JR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Goodwin</surname>
                            <given-names>GM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Rendell</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Azorin</surname>
                            <given-names>JM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cipriani</surname>
                            <given-names>A</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2010</year>
                    <article-title>Lithium plus valproate combination therapy versus monotherapy for
                        relapse prevention in bipolar I disorder (BALANCE): a randomised open-label
                        trial.</article-title>
                    <source>Lancet</source>
                    <volume>375</volume>
                    <fpage>385</fpage>
                    <lpage>395</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Ghaemi3">
                <label>24</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Ghaemi</surname>
                            <given-names>SN</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hsu</surname>
                            <given-names>DJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Thase</surname>
                            <given-names>ME</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Wisniewski</surname>
                            <given-names>SR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Nierenberg</surname>
                            <given-names>AA</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2006</year>
                    <article-title>Pharmacological treatment patterns at study entry for the first
                        500 STEP-BD participants.</article-title>
                    <source>Psychiatr Serv</source>
                    <volume>57</volume>
                    <fpage>660</fpage>
                    <lpage>665</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Lim1">
                <label>25</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Lim</surname>
                            <given-names>PZ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tunis</surname>
                            <given-names>SL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Edell</surname>
                            <given-names>WS</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Jensik</surname>
                            <given-names>SE</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tohen</surname>
                            <given-names>M</given-names>
                        </name>
                    </person-group>
                    <year>2001</year>
                    <article-title>Medication prescribing patterns for patients with bipolar I
                        disorder in hospital settings: adherence to published practice
                        guidelines.</article-title>
                    <source>Bipolar Disord</source>
                    <volume>3</volume>
                    <fpage>165</fpage>
                    <lpage>173</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Frangou1">
                <label>26</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Frangou</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Raymont</surname>
                            <given-names>V</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bettany</surname>
                            <given-names>D</given-names>
                        </name>
                    </person-group>
                    <year>2002</year>
                    <article-title>The Maudsley bipolar disorder project. A survey of psychotropic
                        prescribing patterns in bipolar I disorder.</article-title>
                    <source>Bipolar Disord</source>
                    <volume>4</volume>
                    <fpage>378</fpage>
                    <lpage>385</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Blanco1">
                <label>27</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Blanco</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Laje</surname>
                            <given-names>G</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Olfson</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Marcus</surname>
                            <given-names>SC</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Pincus</surname>
                            <given-names>HA</given-names>
                        </name>
                    </person-group>
                    <year>2002</year>
                    <article-title>Trends in the treatment of bipolar disorder by outpatient
                        psychiatrists.</article-title>
                    <source>Am J Psychiatry</source>
                    <volume>159</volume>
                    <fpage>1005</fpage>
                    <lpage>1010</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Zarate1">
                <label>28</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Tohen</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Baraibar</surname>
                            <given-names>G</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kando</surname>
                            <given-names>JC</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Mirin</surname>
                            <given-names>J</given-names>
                        </name>
                    </person-group>
                    <collab xlink:type="simple">Zarate CA Jr.</collab>
                    <year>1995</year>
                    <article-title>Prescribing trends of antidepressants in bipolar
                        depression.</article-title>
                    <source>J Clin Psychiatry</source>
                    <volume>56</volume>
                    <fpage>260</fpage>
                    <lpage>264</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-US1">
                <label>29</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <collab xlink:type="simple">U.S. Food and Drug Administration</collab>
                    <year>2005</year>
                    <article-title>Approval package for 21-436/S-005 &amp; S-008 &amp;
                        21-713/S-003.</article-title>
                    <publisher-loc>Rockville (Maryland)</publisher-loc>
                    <publisher-name>U.S. Food and Drug Administration</publisher-name>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-IMS1">
                <label>30</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <collab xlink:type="simple">IMS Health</collab>
                    <year>2010</year>
                    <article-title>Top 15 U.S. pharmaceutical products by sales. IMS National Sales
                        Perspectives(TM).</article-title>
                    <publisher-loc>Norwalk</publisher-loc>
                    <publisher-name>IMS Health</publisher-name>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Chow1">
                <label>31</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Chow</surname>
                            <given-names>ST</given-names>
                        </name>
                        <name name-style="western">
                            <surname>von Loesecke</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hohenberg</surname>
                            <given-names>KW</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Epstein</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Buurma</surname>
                            <given-names>AK</given-names>
                        </name>
                    </person-group>
                    <year>2008</year>
                    <article-title>Brands and strategies: atypical antipsychotics.</article-title>
                    <publisher-loc>Waltham (Massachusetts)</publisher-loc>
                    <publisher-name>Decision Resources, Inc</publisher-name>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Diak1">
                <label>32</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Diak</surname>
                            <given-names>I</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Mehta</surname>
                            <given-names>H</given-names>
                        </name>
                    </person-group>
                    <year>2008</year>
                    <article-title>New Molecular Entity review follow-up:
                        aripiprazole.</article-title>
                    <publisher-loc>Rockville (Maryland)</publisher-loc>
                    <publisher-name>U.S. Food and Drug Administration</publisher-name>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Cuttler1">
                <label>33</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Cuttler</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Silvers</surname>
                            <given-names>JB</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Singh</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tsai</surname>
                            <given-names>AC</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Radcliffe</surname>
                            <given-names>D</given-names>
                        </name>
                    </person-group>
                    <year>2005</year>
                    <article-title>Physician decisions to discontinue long-term medications using a
                        two-stage framework: the case of growth hormone therapy.</article-title>
                    <source>Med Care</source>
                    <volume>43</volume>
                    <fpage>1185</fpage>
                    <lpage>1193</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Levit1">
                <label>34</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Levit</surname>
                            <given-names>K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Smith</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cowan</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lazenby</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sensenig</surname>
                            <given-names>A</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2003</year>
                    <article-title>Trends in U.S. health care spending, 2001.</article-title>
                    <source>Health Aff (Millwood)</source>
                    <volume>22</volume>
                    <fpage>154</fpage>
                    <lpage>164</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-BristolMyers1">
                <label>35</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <collab xlink:type="simple">Bristol-Myers Squibb Company</collab>
                    <year>2010</year>
                    <article-title>Clinical trials registry.</article-title>
                    <publisher-loc>New York</publisher-loc>
                    <publisher-name>Bristol Myers Squibb Co</publisher-name>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Gidiere1">
                <label>36</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Gidiere</surname>
                            <given-names>S</given-names>
                        </name>
                    </person-group>
                    <year>2006</year>
                    <article-title>The federal information manual.</article-title>
                    <publisher-loc>Chicago</publisher-loc>
                    <publisher-name>American Bar Association</publisher-name>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Moynihan1">
                <label>37</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Moynihan</surname>
                            <given-names>R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bero</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ross-Degnan</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Henry</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lee</surname>
                            <given-names>K</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2000</year>
                    <article-title>Coverage by the news media of the benefits and risks of
                        medications.</article-title>
                    <source>N Engl J Med</source>
                    <volume>342</volume>
                    <fpage>1645</fpage>
                    <lpage>1650</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Fleiss1">
                <label>38</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Fleiss</surname>
                            <given-names>J</given-names>
                        </name>
                    </person-group>
                    <year>1981</year>
                    <article-title>Statistical methods for rates and proportions. 2nd
                        edition.</article-title>
                    <publisher-loc>New York</publisher-loc>
                    <publisher-name>Wiley</publisher-name>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Keck1">
                <label>39</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Keck</surname>
                            <given-names>PE</given-names>
                            <suffix>Jr</suffix>
                        </name>
                        <name name-style="western">
                            <surname>Calabrese</surname>
                            <given-names>JR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>McQuade</surname>
                            <given-names>RD</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Carson</surname>
                            <given-names>WH</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Carlson</surname>
                            <given-names>BX</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2006</year>
                    <article-title>A randomized, double-blind, placebo-controlled 26-week trial of
                        aripiprazole in recently manic patients with bipolar I
                        disorder.</article-title>
                    <source>J Clin Psychiatry</source>
                    <volume>67</volume>
                    <fpage>626</fpage>
                    <lpage>637</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Keck2">
                <label>40</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Keck</surname>
                            <given-names>PE</given-names>
                            <suffix>Jr</suffix>
                        </name>
                        <name name-style="western">
                            <surname>Calabrese</surname>
                            <given-names>JR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>McIntyre</surname>
                            <given-names>RS</given-names>
                        </name>
                        <name name-style="western">
                            <surname>McQuade</surname>
                            <given-names>RD</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Carson</surname>
                            <given-names>WH</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2007</year>
                    <article-title>Aripiprazole monotherapy for maintenance therapy in bipolar I
                        disorder: a 100-week, double-blind study versus placebo.</article-title>
                    <source>J Clin Psychiatry</source>
                    <volume>68</volume>
                    <fpage>1480</fpage>
                    <lpage>1491</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Otsuka1">
                <label>41</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <collab xlink:type="simple">Otsuka Pharmaceutical Co., Ltd.</collab>
                    <year>2010</year>
                    <article-title>A multicenter, placebo-controlled, double-blind investigative
                        extension trial of the safety and efficacy of aripiprazole in the treatment
                        of patients with bipolar disorder experiencing a manic or mixed episode
                        (NCT00606177).</article-title>
                    <publisher-loc>Tokyo</publisher-loc>
                    <publisher-name>Otsuka Pharmaceutical Co., Ltd</publisher-name>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-BristolMyers2">
                <label>42</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <collab xlink:type="simple">Bristol-Myers Squibb Company</collab>
                    <year>2008</year>
                    <article-title>A multicenter, randomized, double-blind, placebo-controlled study
                        of aripiprazole monotherapy in the treatment of acutely manic patients with
                        bipolar I disorder (CN138-135LT).</article-title>
                    <publisher-loc>New York</publisher-loc>
                    <publisher-name>Bristol-Myers Squibb Co</publisher-name>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Keck3">
                <label>43</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Keck</surname>
                            <given-names>PE</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Orsulak</surname>
                            <given-names>PJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cutler</surname>
                            <given-names>AJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sanchez</surname>
                            <given-names>R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Torbeyns</surname>
                            <given-names>A</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>Aripiprazole monotherapy in the treatment of acute bipolar I
                        mania: a randomized, double-blind, placebo- and lithium-controlled
                        study.</article-title>
                    <source>J Affect Disord</source>
                    <volume>112</volume>
                    <fpage>36</fpage>
                    <lpage>49</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Muzina1">
                <label>44</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Muzina</surname>
                            <given-names>DJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Momah</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Eudicone</surname>
                            <given-names>JM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Pikalov</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>McQuade</surname>
                            <given-names>RD</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2008</year>
                    <article-title>Aripiprazole monotherapy in patients with rapid-cycling bipolar I
                        disorder: an analysis from a long-term, double-blind, placebo-controlled
                        study.</article-title>
                    <source>Int J Clin Pract</source>
                    <volume>62</volume>
                    <fpage>679</fpage>
                    <lpage>687</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Keck4">
                <label>45</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Keck</surname>
                            <given-names>PE</given-names>
                            <suffix>Jr</suffix>
                        </name>
                        <name name-style="western">
                            <surname>Marcus</surname>
                            <given-names>R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tourkodimitris</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ali</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Liebeskind</surname>
                            <given-names>A</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2003</year>
                    <article-title>A placebo-controlled, double-blind study of the efficacy and
                        safety of aripiprazole in patients with acute bipolar mania.</article-title>
                    <source>Am J Psychiatry</source>
                    <volume>160</volume>
                    <fpage>1651</fpage>
                    <lpage>1658</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-He1">
                <label>46</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>He</surname>
                            <given-names>K</given-names>
                        </name>
                    </person-group>
                    <year>2004</year>
                    <article-title>Statistical review and evaluation. Center for Drug Evaluation and
                        Research approval package for 21-436/S-005 &amp; S-008 &amp;
                        21-713/S-003.</article-title>
                    <publisher-loc>Rockville (Maryland)</publisher-loc>
                    <publisher-name>U.S. Food and Drug Administration</publisher-name>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Bowden1">
                <label>47</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Bowden</surname>
                            <given-names>CL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Calabrese</surname>
                            <given-names>JR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sachs</surname>
                            <given-names>G</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Yatham</surname>
                            <given-names>LN</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Asghar</surname>
                            <given-names>SA</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2003</year>
                    <article-title>A placebo-controlled 18-month trial of lamotrigine and lithium
                        maintenance treatment in recently manic or hypomanic patients with bipolar I
                        disorder.</article-title>
                    <source>Arch Gen Psychiatry</source>
                    <volume>60</volume>
                    <fpage>392</fpage>
                    <lpage>400</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Tohen2">
                <label>48</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Tohen</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Calabrese</surname>
                            <given-names>JR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sachs</surname>
                            <given-names>GS</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Banov</surname>
                            <given-names>MD</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Detke</surname>
                            <given-names>HC</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2006</year>
                    <article-title>Randomized, placebo-controlled trial of olanzapine as maintenance
                        therapy in patients with bipolar I disorder responding to acute treatment
                        with olanzapine.</article-title>
                    <source>Am J Psychiatry</source>
                    <volume>163</volume>
                    <fpage>247</fpage>
                    <lpage>256</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Calabrese1">
                <label>49</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Calabrese</surname>
                            <given-names>JR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bowden</surname>
                            <given-names>CL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sachs</surname>
                            <given-names>G</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Yatham</surname>
                            <given-names>LN</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Behnke</surname>
                            <given-names>K</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2003</year>
                    <article-title>A placebo-controlled 18-month trial of lamotrigine and lithium
                        maintenance treatment in recently depressed patients with bipolar I
                        disorder.</article-title>
                    <source>J Clin Psychiatry</source>
                    <volume>64</volume>
                    <fpage>1013</fpage>
                    <lpage>1024</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Angst1">
                <label>50</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Angst</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sellaro</surname>
                            <given-names>R</given-names>
                        </name>
                    </person-group>
                    <year>2000</year>
                    <article-title>Historical perspectives and natural history of bipolar
                        disorder.</article-title>
                    <source>Biol Psychiatry</source>
                    <volume>48</volume>
                    <fpage>445</fpage>
                    <lpage>457</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Tohen3">
                <label>51</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Tohen</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Frank</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bowden</surname>
                            <given-names>CL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Colom</surname>
                            <given-names>F</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ghaemi</surname>
                            <given-names>SN</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>The International Society for Bipolar Disorders (ISBD) Task Force
                        report on the nomenclature of course and outcome in bipolar
                        disorders.</article-title>
                    <source>Bipolar Disord</source>
                    <volume>11</volume>
                    <fpage>453</fpage>
                    <lpage>473</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Ghaemi4">
                <label>52</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Ghaemi</surname>
                            <given-names>SN</given-names>
                        </name>
                    </person-group>
                    <year>2010</year>
                    <article-title>From BALANCE to DSM-5: taking lithium seriously.</article-title>
                    <source>Bipolar Disord</source>
                    <volume>12</volume>
                    <fpage>673</fpage>
                    <lpage>677</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Quitkin1">
                <label>53</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Quitkin</surname>
                            <given-names>FM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Rabkin</surname>
                            <given-names>JG</given-names>
                        </name>
                    </person-group>
                    <year>1981</year>
                    <article-title>Methodological problems in studies of depressive disorder:
                        utility of the discontinuation design.</article-title>
                    <source>J Clin Psychopharmacol</source>
                    <volume>1</volume>
                    <fpage>283</fpage>
                    <lpage>288</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Quitkin2">
                <label>54</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Quitkin</surname>
                            <given-names>F</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Rifkin</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Klein</surname>
                            <given-names>DF</given-names>
                        </name>
                    </person-group>
                    <year>1976</year>
                    <article-title>Prophylaxis of affective disorders. Current status of
                        knowledge.</article-title>
                    <source>Arch Gen Psychiatry</source>
                    <volume>33</volume>
                    <fpage>337</fpage>
                    <lpage>341</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Prodruchny1">
                <label>55</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Prodruchny</surname>
                            <given-names>TA</given-names>
                        </name>
                    </person-group>
                    <year>2004</year>
                    <article-title>Clinical review. Center for Drug Evaluation and Research approval
                        package for 21-436/S-005 &amp; S-008 &amp; 21-713/S-003.</article-title>
                    <publisher-loc>Rockville (Maryland)</publisher-loc>
                    <publisher-name>U.S. Food and Drug Administration</publisher-name>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Ghaemi5">
                <label>56</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Ghaemi</surname>
                            <given-names>SN</given-names>
                        </name>
                    </person-group>
                    <year>2006</year>
                    <article-title>Hippocratic psychopharmacology for bipolar disorder: an
                        expert's opinion.</article-title>
                    <source>Psychiatry (Edgmont)</source>
                    <volume>3</volume>
                    <fpage>30</fpage>
                    <lpage>39</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Deshauer1">
                <label>57</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Deshauer</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Fergusson</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Duffy</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Albuquerque</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Grof</surname>
                            <given-names>P</given-names>
                        </name>
                    </person-group>
                    <year>2005</year>
                    <article-title>Re-evaluation of randomized control trials of lithium
                        monotherapy: a cohort effect.</article-title>
                    <source>Bipolar Disord</source>
                    <volume>7</volume>
                    <fpage>382</fpage>
                    <lpage>387</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Smith1">
                <label>58</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Smith</surname>
                            <given-names>LA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cornelius</surname>
                            <given-names>V</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Warnock</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bell</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Young</surname>
                            <given-names>AH</given-names>
                        </name>
                    </person-group>
                    <year>2007</year>
                    <article-title>Effectiveness of mood stabilizers and antipsychotics in the
                        maintenance phase of bipolar disorder: a systematic review of randomized
                        controlled trials.</article-title>
                    <source>Bipolar Disord</source>
                    <volume>9</volume>
                    <fpage>394</fpage>
                    <lpage>412</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Greenhouse1">
                <label>59</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Greenhouse</surname>
                            <given-names>JB</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Stangl</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kupfer</surname>
                            <given-names>DJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Prien</surname>
                            <given-names>RF</given-names>
                        </name>
                    </person-group>
                    <year>1991</year>
                    <article-title>Methodologic issues in maintenance therapy clinical
                        trials.</article-title>
                    <source>Arch Gen Psychiatry</source>
                    <volume>48</volume>
                    <fpage>313</fpage>
                    <lpage>318</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Wehr1">
                <label>60</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Wehr</surname>
                            <given-names>TA</given-names>
                        </name>
                    </person-group>
                    <year>1990</year>
                    <article-title>Unnecessary confusion about opposite findings in two studies of
                        tricyclic treatment of bipolar illness.</article-title>
                    <source>Arch Gen Psychiatry</source>
                    <volume>47</volume>
                    <fpage>787</fpage>
                    <lpage>788</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Sachs3">
                <label>61</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Sachs</surname>
                            <given-names>GS</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Thase</surname>
                            <given-names>ME</given-names>
                        </name>
                    </person-group>
                    <year>2000</year>
                    <article-title>Bipolar disorder therapeutics: maintenance
                        treatment.</article-title>
                    <source>Biol Psychiatry</source>
                    <volume>48</volume>
                    <fpage>573</fpage>
                    <lpage>581</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Shapiro1">
                <label>62</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Shapiro</surname>
                            <given-names>DR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Quitkin</surname>
                            <given-names>FM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Fleiss</surname>
                            <given-names>JL</given-names>
                        </name>
                    </person-group>
                    <year>1990</year>
                    <article-title>Unnecessary confusion about opposite findings in two studies of
                        tricyclic treatment of bipolar illness. Reply.</article-title>
                    <source>Arch Gen Psychiatry</source>
                    <volume>47</volume>
                    <fpage>788</fpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Deshauer2">
                <label>63</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Deshauer</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Moher</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Fergusson</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Moher</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sampson</surname>
                            <given-names>M</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2008</year>
                    <article-title>Selective serotonin reuptake inhibitors for unipolar depression:
                        a systematic review of classic long-term randomized controlled
                        trials.</article-title>
                    <source>CMAJ</source>
                    <volume>178</volume>
                    <fpage>1293</fpage>
                    <lpage>1301</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Levenson1">
                <label>64</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Levenson</surname>
                            <given-names>M</given-names>
                        </name>
                    </person-group>
                    <year>2008</year>
                    <article-title>Antiepileptic drugs and suicidality.</article-title>
                    <publisher-loc>Rockville (Maryland)</publisher-loc>
                    <publisher-name>U.S. Food and Drug Administration</publisher-name>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Stone1">
                <label>65</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Stone</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Laughren</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Jones</surname>
                            <given-names>ML</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Levenson</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Holland</surname>
                            <given-names>PC</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>Risk of suicidality in clinical trials of antidepressants in
                        adults: analysis of proprietary data submitted to US Food and Drug
                        Administration.</article-title>
                    <source>BMJ</source>
                    <volume>339</volume>
                    <fpage>b2880</fpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Calabrese2">
                <label>66</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Calabrese</surname>
                            <given-names>JR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Rapport</surname>
                            <given-names>DJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Shelton</surname>
                            <given-names>MD</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kimmel</surname>
                            <given-names>SE</given-names>
                        </name>
                    </person-group>
                    <year>2001</year>
                    <article-title>Evolving methodologies in bipolar disorder maintenance
                        research.</article-title>
                    <source>Br J Psychiatry</source>
                    <volume>Suppl 41</volume>
                    <fpage>s157</fpage>
                    <lpage>163</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Calabrese3">
                <label>67</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Calabrese</surname>
                            <given-names>JR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Rapport</surname>
                            <given-names>DJ</given-names>
                        </name>
                    </person-group>
                    <year>1999</year>
                    <article-title>Mood stabilizers and the evolution of maintenance study designs
                        in bipolar I disorder.</article-title>
                    <source>J Clin Psychiatry</source>
                    <volume>60</volume>
                    <supplement>Suppl 5</supplement>
                    <fpage>5</fpage>
                    <lpage>13; discussion 14-15</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Lapierre1">
                <label>68</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Lapierre</surname>
                            <given-names>YD</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Gagnon</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kokkinidis</surname>
                            <given-names>L</given-names>
                        </name>
                    </person-group>
                    <year>1980</year>
                    <article-title>Rapid recurrence of mania following lithium
                        withdrawal.</article-title>
                    <source>Biol Psychiatry</source>
                    <volume>15</volume>
                    <fpage>859</fpage>
                    <lpage>864</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Mander1">
                <label>69</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Mander</surname>
                            <given-names>AJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Loudon</surname>
                            <given-names>JB</given-names>
                        </name>
                    </person-group>
                    <year>1988</year>
                    <article-title>Rapid recurrence of mania following abrupt discontinuation of
                        lithium.</article-title>
                    <source>Lancet</source>
                    <volume>2</volume>
                    <fpage>15</fpage>
                    <lpage>17</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Baldessarini1">
                <label>70</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Baldessarini</surname>
                            <given-names>RJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Suppes</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tondo</surname>
                            <given-names>L</given-names>
                        </name>
                    </person-group>
                    <year>1996</year>
                    <article-title>Lithium withdrawal in bipolar disorder: implications for clinical
                        practice and experimental therapeutics research.</article-title>
                    <source>Am J Ther</source>
                    <volume>3</volume>
                    <fpage>492</fpage>
                    <lpage>496</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Suppes3">
                <label>71</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Suppes</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Baldessarini</surname>
                            <given-names>RJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Faedda</surname>
                            <given-names>GL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tondo</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tohen</surname>
                            <given-names>M</given-names>
                        </name>
                    </person-group>
                    <year>1993</year>
                    <article-title>Discontinuation of maintenance treatment in bipolar disorder:
                        risks and implications.</article-title>
                    <source>Harv Rev Psychiatry</source>
                    <volume>1</volume>
                    <fpage>131</fpage>
                    <lpage>144</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Faedda1">
                <label>72</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Faedda</surname>
                            <given-names>GL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tondo</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Baldessarini</surname>
                            <given-names>RJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Suppes</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tohen</surname>
                            <given-names>M</given-names>
                        </name>
                    </person-group>
                    <year>1993</year>
                    <article-title>Outcome after rapid vs gradual discontinuation of lithium
                        treatment in bipolar disorders.</article-title>
                    <source>Arch Gen Psychiatry</source>
                    <volume>50</volume>
                    <fpage>448</fpage>
                    <lpage>455</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Baldessarini2">
                <label>73</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Baldessarini</surname>
                            <given-names>RJ</given-names>
                        </name>
                    </person-group>
                    <year>1995</year>
                    <article-title>Risks and implications of interrupting maintenance psychotropic
                        drug therapy.</article-title>
                    <source>Psychother Psychosom</source>
                    <volume>63</volume>
                    <fpage>137</fpage>
                    <lpage>141</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Baldessarini3">
                <label>74</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Baldessarini</surname>
                            <given-names>RJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tondo</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Faedda</surname>
                            <given-names>GL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Suppes</surname>
                            <given-names>TR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Floris</surname>
                            <given-names>G</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>1996</year>
                    <article-title>Effects of the rate of discontinuing lithium maintenance
                        treatment in bipolar disorders.</article-title>
                    <source>J Clin Psychiatry</source>
                    <volume>57</volume>
                    <fpage>441</fpage>
                    <lpage>448</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Baldessarini4">
                <label>75</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Baldessarini</surname>
                            <given-names>RJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tondo</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ghiani</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lepri</surname>
                            <given-names>B</given-names>
                        </name>
                    </person-group>
                    <year>2010</year>
                    <article-title>Illness risk following rapid versus gradual discontinuation of
                        antidepressants.</article-title>
                    <source>Am J Psychiatry</source>
                    <volume>167</volume>
                    <fpage>934</fpage>
                    <lpage>941</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Suppes4">
                <label>76</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Suppes</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Baldessarini</surname>
                            <given-names>RJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Faedda</surname>
                            <given-names>GL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tohen</surname>
                            <given-names>M</given-names>
                        </name>
                    </person-group>
                    <year>1991</year>
                    <article-title>Risk of recurrence following discontinuation of lithium treatment
                        in bipolar disorder.</article-title>
                    <source>Arch Gen Psychiatry</source>
                    <volume>48</volume>
                    <fpage>1082</fpage>
                    <lpage>1088</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Goodwin3">
                <label>77</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Goodwin</surname>
                            <given-names>GM</given-names>
                        </name>
                    </person-group>
                    <year>1994</year>
                    <article-title>Recurrence of mania after lithium withdrawal. Implications for
                        the use of lithium in the treatment of bipolar affective
                        disorder.</article-title>
                    <source>Br J Psychiatry</source>
                    <volume>164</volume>
                    <fpage>149</fpage>
                    <lpage>152</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Franks1">
                <label>78</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Franks</surname>
                            <given-names>MA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Macritchie</surname>
                            <given-names>KA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Mahmood</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Young</surname>
                            <given-names>AH</given-names>
                        </name>
                    </person-group>
                    <year>2008</year>
                    <article-title>Bouncing back: is the bipolar rebound phenomenon peculiar to
                        lithium? A retrospective naturalistic study.</article-title>
                    <source>J Psychopharmacol</source>
                    <volume>22</volume>
                    <fpage>452</fpage>
                    <lpage>456</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Viguera1">
                <label>79</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Viguera</surname>
                            <given-names>AC</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Baldessarini</surname>
                            <given-names>RJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hegarty</surname>
                            <given-names>JD</given-names>
                        </name>
                        <name name-style="western">
                            <surname>van Kammen</surname>
                            <given-names>DP</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tohen</surname>
                            <given-names>M</given-names>
                        </name>
                    </person-group>
                    <year>1997</year>
                    <article-title>Clinical risk following abrupt and gradual withdrawal of
                        maintenance neuroleptic treatment.</article-title>
                    <source>Arch Gen Psychiatry</source>
                    <volume>54</volume>
                    <fpage>49</fpage>
                    <lpage>55</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Baldessarini5">
                <label>80</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Baldessarini</surname>
                            <given-names>RJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Viguera</surname>
                            <given-names>AC</given-names>
                        </name>
                    </person-group>
                    <year>1998</year>
                    <article-title>Medication removal and research in psychotic
                        disorders.</article-title>
                    <source>Arch Gen Psychiatry</source>
                    <volume>55</volume>
                    <fpage>281</fpage>
                    <lpage>283</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Healy3">
                <label>81</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Healy</surname>
                            <given-names>D</given-names>
                        </name>
                    </person-group>
                    <year>2010</year>
                    <article-title>Treatment-induced stress syndromes.</article-title>
                    <source>Med Hypotheses</source>
                    <volume>74</volume>
                    <fpage>764</fpage>
                    <lpage>768</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Geddes2">
                <label>82</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Geddes</surname>
                            <given-names>JR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Burgess</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hawton</surname>
                            <given-names>K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Jamison</surname>
                            <given-names>K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Goodwin</surname>
                            <given-names>GM</given-names>
                        </name>
                    </person-group>
                    <year>2004</year>
                    <article-title>Long-term lithium therapy for bipolar disorder: systematic review
                        and meta-analysis of randomized controlled trials.</article-title>
                    <source>Am J Psychiatry</source>
                    <volume>161</volume>
                    <fpage>217</fpage>
                    <lpage>222</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Bowden2">
                <label>83</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Bowden</surname>
                            <given-names>CL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Calabrese</surname>
                            <given-names>JR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>McElroy</surname>
                            <given-names>SL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Gyulai</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Wassef</surname>
                            <given-names>A</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2000</year>
                    <article-title>A randomized, placebo-controlled 12-month trial of divalproex and
                        lithium in treatment of outpatients with bipolar I disorder. Divalproex
                        Maintenance Study Group.</article-title>
                    <source>Arch Gen Psychiatry</source>
                    <volume>57</volume>
                    <fpage>481</fpage>
                    <lpage>489</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Bowden3">
                <label>84</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Bowden</surname>
                            <given-names>CL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Swann</surname>
                            <given-names>AC</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Calabrese</surname>
                            <given-names>JR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>McElroy</surname>
                            <given-names>SL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Morris</surname>
                            <given-names>D</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>1997</year>
                    <article-title>Maintenance clinical trials in bipolar disorder: design
                        implications of the divalproex-lithium-placebo study.</article-title>
                    <source>Psychopharmacol Bull</source>
                    <volume>33</volume>
                    <fpage>693</fpage>
                    <lpage>699</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Coppen1">
                <label>85</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Coppen</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Noguera</surname>
                            <given-names>R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bailey</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Burns</surname>
                            <given-names>BH</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Swani</surname>
                            <given-names>MS</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>1971</year>
                    <article-title>Prophylactic lithium in affective disorders. Controlled
                        trial.</article-title>
                    <source>Lancet</source>
                    <volume>2</volume>
                    <fpage>275</fpage>
                    <lpage>279</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Prien1">
                <label>86</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Prien</surname>
                            <given-names>RF</given-names>
                        </name>
                    </person-group>
                    <collab xlink:type="simple">Caffey EMJr., Klett CJ</collab>
                    <year>1973</year>
                    <article-title>Prophylactic efficacy of lithium carbonate in manic-depressive
                        illness. Report of the Veterans Administration and National Institute of
                        Mental Health collaborative study group.</article-title>
                    <source>Arch Gen Psychiatry</source>
                    <volume>28</volume>
                    <fpage>337</fpage>
                    <lpage>341</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Kemp1">
                <label>87</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Kemp</surname>
                            <given-names>DE</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Canan</surname>
                            <given-names>F</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Goldstein</surname>
                            <given-names>BI</given-names>
                        </name>
                        <name name-style="western">
                            <surname>McIntyre</surname>
                            <given-names>RS</given-names>
                        </name>
                    </person-group>
                    <year>2009</year>
                    <article-title>Long-acting risperidone: a review of its role in the treatment of
                        bipolar disorder.</article-title>
                    <source>Adv Ther</source>
                    <volume>26</volume>
                    <fpage>588</fpage>
                    <lpage>599</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Fountoulakis1">
                <label>88</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Fountoulakis</surname>
                            <given-names>KN</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Vieta</surname>
                            <given-names>E</given-names>
                        </name>
                    </person-group>
                    <year>2009</year>
                    <article-title>Efficacy and safety of aripiprazole in the treatment of bipolar
                        disorder: a systematic review.</article-title>
                    <source>Ann Gen Psychiatry</source>
                    <volume>8</volume>
                    <fpage>16</fpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Muzina2">
                <label>89</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Muzina</surname>
                            <given-names>DJ</given-names>
                        </name>
                    </person-group>
                    <year>2009</year>
                    <article-title>Treatment and prevention of mania in bipolar I disorder: focus on
                        aripiprazole.</article-title>
                    <source>Neuropsychiatr Dis Treat</source>
                    <volume>5</volume>
                    <fpage>279</fpage>
                    <lpage>288</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-McIntyre1">
                <label>90</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>McIntyre</surname>
                            <given-names>RS</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Woldeyohannes</surname>
                            <given-names>HO</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Yasgur</surname>
                            <given-names>BS</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Soczynska</surname>
                            <given-names>JK</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Miranda</surname>
                            <given-names>A</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2007</year>
                    <article-title>Maintenance treatment in bipolar disorder: a focus on
                        aripiprazole.</article-title>
                    <source>Expert Rev Neurother</source>
                    <volume>7</volume>
                    <fpage>919</fpage>
                    <lpage>925</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-McIntyre2">
                <label>91</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>McIntyre</surname>
                            <given-names>RS</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Soczynska</surname>
                            <given-names>JK</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Woldeyohannes</surname>
                            <given-names>HO</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Miranda</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Konarski</surname>
                            <given-names>JZ</given-names>
                        </name>
                    </person-group>
                    <year>2007</year>
                    <article-title>Aripiprazole: pharmacology and evidence in bipolar
                        disorder.</article-title>
                    <source>Expert Opin Pharmacother</source>
                    <volume>8</volume>
                    <fpage>1001</fpage>
                    <lpage>1009</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-McIntyre3">
                <label>92</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>McIntyre</surname>
                            <given-names>RS</given-names>
                        </name>
                    </person-group>
                    <year>2010</year>
                    <article-title>Aripiprazole for the maintenance treatment of bipolar I disorder:
                        a review.</article-title>
                    <source>Clin Ther</source>
                    <volume>32</volume>
                    <supplement>Suppl 1</supplement>
                    <fpage>S32</fpage>
                    <lpage>38</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-GarciaAmador1">
                <label>93</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Garcia-Amador</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Pacchiarotti</surname>
                            <given-names>I</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Valenti</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sanchez</surname>
                            <given-names>RF</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Goikolea</surname>
                            <given-names>JM</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2006</year>
                    <article-title>Role of aripiprazole in treating mood disorders.</article-title>
                    <source>Expert Rev Neurother</source>
                    <volume>6</volume>
                    <fpage>1777</fpage>
                    <lpage>1783</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Fagiolini1">
                <label>94</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Fagiolini</surname>
                            <given-names>A</given-names>
                        </name>
                    </person-group>
                    <year>2008</year>
                    <article-title>Practical guidance for prescribing with aripiprazole in bipolar
                        disorder.</article-title>
                    <source>Curr Med Res Opin</source>
                    <volume>24</volume>
                    <fpage>2691</fpage>
                    <lpage>2702</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Ulusahin1">
                <label>95</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Ulusahin</surname>
                            <given-names>A</given-names>
                        </name>
                    </person-group>
                    <year>2008</year>
                    <article-title>Ikiuclu bozuklukta aripiprazol [Aripiprazole for the
                        treatment of bipolar disorder].</article-title>
                    <source>Klinik Psikofarmakoloji Bulteni [Bulletin of Clinical
                        Psychopharmacology]</source>
                    <volume>18</volume>
                    <fpage>S27</fpage>
                    <lpage>S34</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Yatham1">
                <label>96</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Yatham</surname>
                            <given-names>LN</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kennedy</surname>
                            <given-names>SH</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Schaffer</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Parikh</surname>
                            <given-names>SV</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Beaulieu</surname>
                            <given-names>S</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2009</year>
                    <article-title>Canadian Network for Mood and Anxiety Treatments (CANMAT) and
                        International Society for Bipolar Disorders (ISBD) collaborative update of
                        CANMAT guidelines for the management of patients with bipolar disorder:
                        update 2009.</article-title>
                    <source>Bipolar Disord</source>
                    <volume>11</volume>
                    <fpage>225</fpage>
                    <lpage>255</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Goodwin4">
                <label>97</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Goodwin</surname>
                            <given-names>GM</given-names>
                        </name>
                    </person-group>
                    <year>2009</year>
                    <article-title>Evidence-based guidelines for treating bipolar disorder: revised
                        second edition—recommendations from the British Association for
                        Psychopharmacology.</article-title>
                    <source>J Psychopharmacol</source>
                    <volume>23</volume>
                    <fpage>346</fpage>
                    <lpage>388</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Forbes1">
                <label>98</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Forbes</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Findling</surname>
                            <given-names>RL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Nyilas</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Forbes</surname>
                            <given-names>RA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Aurang</surname>
                            <given-names>C</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2008</year>
                    <article-title>Long-term efficacy of aripiprazole in pediatric patients with
                        bipolar I disorder.</article-title>
                    <source>New Research Abstracts; May 3-8 American Psychiatric
                        Association</source>
                    <volume>297</volume>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Baldessarini6">
                <label>99</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Baldessarini</surname>
                            <given-names>RJ</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tohen</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tondo</surname>
                            <given-names>L</given-names>
                        </name>
                    </person-group>
                    <year>2000</year>
                    <article-title>Maintenance treatment in bipolar disorder.</article-title>
                    <source>Arch Gen Psychiatry</source>
                    <volume>57</volume>
                    <fpage>490</fpage>
                    <lpage>492</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Goodwin5">
                <label>100</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Goodwin</surname>
                            <given-names>GM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Malhi</surname>
                            <given-names>GS</given-names>
                        </name>
                    </person-group>
                    <year>2007</year>
                    <article-title>What is a mood stabilizer?</article-title>
                    <source>Psychol Med</source>
                    <volume>37</volume>
                    <fpage>609</fpage>
                    <lpage>614</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Bowden4">
                <label>101</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Bowden</surname>
                            <given-names>CL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Calabrese</surname>
                            <given-names>JR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Wallin</surname>
                            <given-names>BA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Swann</surname>
                            <given-names>AC</given-names>
                        </name>
                        <name name-style="western">
                            <surname>McElroy</surname>
                            <given-names>SL</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>1995</year>
                    <article-title>Illness characteristics of patients in clinical drug studies of
                        mania.</article-title>
                    <source>Psychopharmacol Bull</source>
                    <volume>31</volume>
                    <fpage>103</fpage>
                    <lpage>109</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Post1">
                <label>102</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Post</surname>
                            <given-names>RM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Keck</surname>
                            <given-names>P</given-names>
                            <suffix>Jr</suffix>
                        </name>
                        <name name-style="western">
                            <surname>Rush</surname>
                            <given-names>AJ</given-names>
                        </name>
                    </person-group>
                    <year>2002</year>
                    <article-title>New designs for studies of the prophylaxis of bipolar
                        disorder.</article-title>
                    <source>J Clin Psychopharmacol</source>
                    <volume>22</volume>
                    <fpage>1</fpage>
                    <lpage>3</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Prien2">
                <label>103</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Prien</surname>
                            <given-names>RF</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kupfer</surname>
                            <given-names>DJ</given-names>
                        </name>
                    </person-group>
                    <year>1989</year>
                    <article-title>Outside analysis of a multicenter collaborative
                        study.</article-title>
                    <source>Arch Gen Psychiatry</source>
                    <volume>46</volume>
                    <fpage>462</fpage>
                    <lpage>464</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Tohen4">
                <label>104</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Tohen</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lin</surname>
                            <given-names>D</given-names>
                        </name>
                    </person-group>
                    <year>2006</year>
                    <article-title>Maintenance treatment in bipolar disorder.</article-title>
                    <source>Psychiatry (Edgmont)</source>
                    <volume>3</volume>
                    <fpage>43</fpage>
                    <lpage>45</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Swann1">
                <label>105</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Swann</surname>
                            <given-names>AC</given-names>
                        </name>
                    </person-group>
                    <year>2006</year>
                    <article-title>Treating bipolar disorder: for the patient or against the
                        illness?</article-title>
                    <source>Psychiatry (Edgmont)</source>
                    <volume>3</volume>
                    <fpage>40</fpage>
                    <lpage>42</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Mallinckrodt1">
                <label>106</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Mallinckrodt</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Chuang-Stein</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>McSorley</surname>
                            <given-names>P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Schwartz</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Archibald</surname>
                            <given-names>DG</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2007</year>
                    <article-title>A case study comparing a randomized withdrawal trial and a
                        double-blind long-term trial for assessing the long-term efficacy of an
                        antidepressant.</article-title>
                    <source>Pharm Stat</source>
                    <volume>6</volume>
                    <fpage>9</fpage>
                    <lpage>22</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Amery1">
                <label>107</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Amery</surname>
                            <given-names>W</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Dony</surname>
                            <given-names>J</given-names>
                        </name>
                    </person-group>
                    <year>1975</year>
                    <article-title>A clinical trial design avoiding undue placebo
                        treatment.</article-title>
                    <source>J Clin Pharmacol</source>
                    <volume>15</volume>
                    <fpage>674</fpage>
                    <lpage>679</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Temple1">
                <label>108</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Temple</surname>
                            <given-names>R</given-names>
                        </name>
                    </person-group>
                    <year>1989</year>
                    <article-title>Government viewpoint of clinical trials of cardiovascular
                        drugs.</article-title>
                    <source>Med Clin North Am</source>
                    <volume>73</volume>
                    <fpage>495</fpage>
                    <lpage>509</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Peselow1">
                <label>109</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Peselow</surname>
                            <given-names>ED</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Fieve</surname>
                            <given-names>RR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Difiglia</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sanfilipo</surname>
                            <given-names>MP</given-names>
                        </name>
                    </person-group>
                    <year>1994</year>
                    <article-title>Lithium prophylaxis of bipolar illness. The value of combination
                        treatment.</article-title>
                    <source>Br J Psychiatry</source>
                    <volume>164</volume>
                    <fpage>208</fpage>
                    <lpage>214</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Ghaemi6">
                <label>110</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Ghaemi</surname>
                            <given-names>SN</given-names>
                        </name>
                    </person-group>
                    <year>2008</year>
                    <article-title>Toward a Hippocratic psychopharmacology.</article-title>
                    <source>Can J Psychiatry</source>
                    <volume>53</volume>
                    <fpage>189</fpage>
                    <lpage>196</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Carey1">
                <label>111</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Carey</surname>
                            <given-names>TS</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Williams</surname>
                            <given-names>JW</given-names>
                            <suffix>Jr</suffix>
                        </name>
                        <name name-style="western">
                            <surname>Oldham</surname>
                            <given-names>JM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Goodman</surname>
                            <given-names>F</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ranney</surname>
                            <given-names>LM</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2008</year>
                    <article-title>Gabapentin in the treatment of mental illness: the echo chamber
                        of the case series.</article-title>
                    <source>J Psychiatr Pract</source>
                    <volume>14</volume>
                    <supplement>Suppl 1</supplement>
                    <fpage>15</fpage>
                    <lpage>27</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Choudhry1">
                <label>112</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Choudhry</surname>
                            <given-names>NK</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Stelfox</surname>
                            <given-names>HT</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Detsky</surname>
                            <given-names>AS</given-names>
                        </name>
                    </person-group>
                    <year>2002</year>
                    <article-title>Relationships between authors of clinical practice guidelines and
                        the pharmaceutical industry.</article-title>
                    <source>JAMA</source>
                    <volume>287</volume>
                    <fpage>612</fpage>
                    <lpage>617</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Stelfox1">
                <label>113</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Stelfox</surname>
                            <given-names>HT</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Chua</surname>
                            <given-names>G</given-names>
                        </name>
                        <name name-style="western">
                            <surname>O'Rourke</surname>
                            <given-names>K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Detsky</surname>
                            <given-names>AS</given-names>
                        </name>
                    </person-group>
                    <year>1998</year>
                    <article-title>Conflict of interest in the debate over calcium-channel
                        antagonists.</article-title>
                    <source>N Engl J Med</source>
                    <volume>338</volume>
                    <fpage>101</fpage>
                    <lpage>106</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Abramson1">
                <label>114</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Abramson</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Starfield</surname>
                            <given-names>B</given-names>
                        </name>
                    </person-group>
                    <year>2005</year>
                    <article-title>The effect of conflict of interest on biomedical research and
                        clinical practice guidelines: can we trust the evidence in evidence-based
                        medicine?</article-title>
                    <source>J Am Board Fam Pract</source>
                    <volume>18</volume>
                    <fpage>414</fpage>
                    <lpage>418</lpage>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Rising1">
                <label>115</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Rising</surname>
                            <given-names>K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bacchetti</surname>
                            <given-names>P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bero</surname>
                            <given-names>L</given-names>
                        </name>
                    </person-group>
                    <year>2008</year>
                    <article-title>Reporting bias in drug trials submitted to the Food and Drug
                        Administration: review of publication and presentation.</article-title>
                    <source>PLoS Med</source>
                    <volume>5</volume>
                    <fpage>e217; discussion e217</fpage>
                    <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0050217" xlink:type="simple">10.1371/journal.pmed.0050217</ext-link></comment>
                </element-citation>
            </ref>
            <ref id="pmed.1000434-Lexchin1">
                <label>116</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Lexchin</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bero</surname>
                            <given-names>LA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Djulbegovic</surname>
                            <given-names>B</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Clark</surname>
                            <given-names>O</given-names>
                        </name>
                    </person-group>
                    <year>2003</year>
                    <article-title>Pharmaceutical industry sponsorship and research outcome and
                        quality: systematic review.</article-title>
                    <source>BMJ</source>
                    <volume>326</volume>
                    <fpage>1167</fpage>
                    <lpage>1170</lpage>
                </element-citation>
            </ref>
        </ref-list>
        <glossary>
            <title>Abbreviations</title>
            <def-list>
                <def-item>
                    <term>CI</term>
                    <def>
                        <p>confidence interval</p>
                    </def>
                </def-item>
                <def-item>
                    <term>NDA</term>
                    <def>
                        <p>new drug application</p>
                    </def>
                </def-item>
            </def-list>
        </glossary>
        
    </back>
</article>